

An acute microglial metabolic response controls metabolism and improves memory

Reviewed Preprint

v2 • June 24, 2024

Revised by authors

Reviewed Preprint

v1 • June 5, 2023

Anne Drougard , Eric H Ma, Vanessa Wegert, Ryan Sheldon, Ilaria Panzeri, Naman Vatsa, Stefanos Apostle, Luca Fagnocchi, Judith Schaf, Klaus Gossens, Josephine Völker, Shengru Pang, Anna Bremser, Erez Dror, Francesca Giacona, Sagar, Michael X Henderson, Marco Prinz, Russell G Jones, J. Andrew Pospisilik 


Department of Epigenetics, Van Andel Research Institute, 333 Bostwick Ave, 49503, Grand Rapids, MI, USA • Max Planck Institute of Immunobiology and Epigenetics, Stübeweg 51, 79108 Freiburg, Germany • Department of Metabolism and Nutritional Programming, Van Andel Research Institute, 333 Bostwick Ave, 49503, Grand Rapids, MI, USA • Metabolomics and Bioenergetics Core, Van Andel Research Institute, 333 Bostwick Ave, 49503, Grand Rapids, MI, USA • Department of Neurodegenerative Sciences, Van Andel Research Institute, 333 Bostwick Ave, 49503, Grand Rapids, MI, USA • Institute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany • Department of Medicine II, University Hospital Freiburg, Freiburg, Germany • Centre for NeuroModulation (NeuroModBasics), University of Freiburg, Freiburg, Germany • Signaling Research Centers BIOSS and CIBSS, University of Freiburg, Freiburg, Germany

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

Chronic high-fat feeding triggers chronic metabolic dysfunction including obesity, insulin resistance, and diabetes. How high-fat intake first triggers these pathophysiological states remains unknown. Here, we identify an acute microglial metabolic response that rapidly translates intake of high-fat diet (HFD) to a surprisingly beneficial effect on metabolism and spatial / learning memory. High-fat intake rapidly increases palmitate levels in cerebrospinal fluid and triggers a wave of microglial metabolic activation characterized by mitochondrial membrane activation and fission as well as metabolic skewing towards aerobic glycolysis. These effects are detectable throughout the brain and can be detected within as little as 12 hours of HFD exposure. In vivo, microglial ablation and conditional DRP1 deletion show that the microglial metabolic response is necessary for the acute effects of HFD. ¹³C-tracing experiments reveal that in addition to processing via β -oxidation, microglia shunt a substantial fraction of palmitate towards anaplerosis and re-release of bioenergetic carbons into the extracellular milieu in the form of lactate, glutamate, succinate, and intriguingly, the neuro-protective metabolite itaconate. Together, these data identify microglia as a critical nutrient regulatory node in the brain, metabolizing away harmful fatty acids and releasing the same carbons as alternate bioenergetic and protective substrates for surrounding cells. The data identify a surprisingly beneficial effect of short-term HFD on learning and memory.



eLife assessment

This **important** study demonstrates a link between an acute high fat diet, microglial metabolism and improved higher cognitive function. The evidence supporting the proposed mechanism in vivo is **incomplete** at this stage due to non-trivial technical limitations but the authors provide **convincing** in vitro metabolic characterization of primary microglia cultures to support the model. This work will be of interest to a broad audience in the field of neuroscience, metabolism, and immunology.

<https://doi.org/10.7554/eLife.87120.2.sa3>

Introduction

The central nervous system (CNS) plays a critical role in regulating glucose and energy homeostasis by sensing, integrating, and responding to peripheral signals [1]. Our understanding of CNS control over energy balance is mostly derived from investigation of distinct functional sets of hypothalamic neurons and their interactions with the periphery [2]. In addition, a growing body of evidence supports an important role for glial cells in regulating energy balance [3]. For example, astrocytes can regulate energy balance by processing glucose into lactate, which is then released to fuel and modulate surrounding neurons [4], [5], [6], [7]. These latter findings demonstrate how metabolic intermediaries from the neuronal niche can directly influence CNS output.

Microglia are the third most abundant glial cell in the brain. Developmentally, they are derived from the yolk sac and are considered CNS immune cells. Like the peripheral immune compartment, microglia activation has been implicated in metabolic disease pathogenesis [8], [9], [10]. Specifically, microglia in the mediobasal hypothalamus (MBH) become activated under conditions of chronic high-fat feeding in a process termed ‘microgliosis’. High fat diet (HFD)-induced activation has been associated with moderate increases in cytokine gene expression [8], [11] and pioneering studies testing both genetic manipulation of microglial NF- κ B and microglial depletion with PLX5622 suggest that microglial activation is necessary for the metabolic impairments triggered by chronic HFD [9]. Recent evidence suggests a role for microglial mitochondrial alterations (fission) that can be detected within days of high fat diet (HFD) administration [10]. Microglia outside the hypothalamus also activate upon chronic HFD exposure [12], [13] and associate with cognitive impairment [14], [15]. A key outstanding question in the field, then, is how high-fat feeding first triggers microglial activation.

Here, we find that microglia respond to dietary fat within a single 12-hour feeding cycle. By three days, HFD increases microglial mitochondrial membrane potential, inhibits complex II activity, and skews mitochondria towards fission. Using cerebrospinal fluid (CSF) metabolomics we demonstrate that microglia are directly exposed to increased palmitate and stearate levels within hours of the feeding switch, and using ^{13}C -tracer studies, we find that microglia robustly metabolize fatty acids via β -oxidation. Interestingly, we find the same acute microglial metabolic response (aMMR) beyond the hypothalamus *in vivo*, in the hippocampus and cortex. aMMR is largely independent of transcriptional changes, and intriguingly, we find that it improves spatial and learning memory. Microglial depletion experiments and microglia-specific DRP deletion show that microglia and more specifically microglial mitochondrial fission, are necessary for both the immediate whole-body glucose homeostatic response and the memory improvements to acute HFD. The data thus identify an acute non-transcriptional microglial metabolic pathway that couples detection of increased dietary fat to changes in whole body metabolism and memory.

Results

Acute HFD-induced metabolic changes are microglia dependent

To understand the nature of the immediate high-fat feeding response, we characterized the physiological effects of acute HFD (3d *ad libitum* feeding) in cohorts of C57BL/6J mice (Fig 1A). Metabolically healthy mice exhibit rapid metabolic shifts on this timescale, including fasting and post-absorptive (2-hr fast) hyperglycemia and an elevated insulin response to glucose (Fig 1B-E, Suppl Fig S1A-B) [16], [17]. Glucose excursions, as revealed by baseline-correction, and insulin tolerance test results are minimally impacted upon acute HFD (Suppl Fig S1C), an important contrast to chronic HFD [18]. These acute changes in glycemic control are transient, returning to homeostatic levels within one week of a return to normal chow (‘Reverse Diet’; Fig 1C-E) and are not associated with substantial body weight gain (Suppl Fig S1D). To test whether microglia contribute these effects, we treated mice with the microglia-ablating drug PLX-5622 [19] for 7-9 days and repeated the 3d HFD metabolic assessment. PLX-5622 treatment depleted hypothalamic microglia by >95% across animals (Fig 1F), without body weight gain or food intake modification (Suppl Fig S6A-B) and prevented both the 3d HFD insulin hypersecretion and post-absorptive hyperglycemia (Fig 1C-E). Hyperglycemia associated with over-night fasting was unaffected by microglial depletion (Fig 1C). The latter indicates that acute HFD triggers microglia-dependent and independent metabolic effects. Thus, microglia are required for metabolic changes induced by the transition to high-fat feeding.




FIGURE 1

Acute HFD-induced metabolic changes are microglia dependent

A. Schematic depicting the different treatments and diets followed by the different mice groups.

B. Graphs showing the Glucose Tolerance Test (OGTT) and the associated-insulin kinetic of C57Bl6/J male fed with control diet (Control) or fed with high fat diet for 3 days (3-day HFD) (n=8).

C. Graph showing the overnight fasted glycemia from the mice groups depicting in the **A**. Schematic (n=5 to 11).

D. Graph showing the 2hours-fast glycemia from the mice groups depicting in the **A**. schematic (n=5 to 11).

E. Graph showing the insulin released after a glucose gavage from the mice groups depicting in the **A**. schematic (n=5 to 11).

F. Microglial cells staining with Iba1 (green) in the brain slices from mice fed with 3 days HFD or mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 prior the 3 days HFD (PLX-5662) (n=5).

G. sgRNAseq dataset from hypothalamic microglia cells harvested from C57Bl6/J male mice fed with control diet (CT) and High Fat Diet for 3 days (HFD_3d) (n=5) merged with sgRNAseq microglia dataset from mice presenting an Experimental Autoimmune Encephalomyelitis (EAE). Data are presented as mean $\pm$ SEM. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc test.

A rapid Microglial Mitochondria Response to high fat diet

Long-term exposure to HFD has previously been associated with hypothalamic microgliosis (increased number and activation of CD45^{lo};CD11b⁺ microglia) and monocyte infiltration (CD45^{hi};Cd11b⁺) [9]. Examination of 3d HFD responses in both wild-type animals and animals harboring a microglia-restricted EYFP lineage reporter showed no evidence of either increased hypothalamic microglial proliferation (Suppl Fig S1E) or monocyte infiltration (Suppl Fig S1F). Similarly, using one of the most sensitive scRNAseq protocols available (CEL-Seq2), we found no evidence of a significant microglial transcriptional response to this very short term HFD exposure. The latter analysis included searches for changes in heterogeneity, skewing across sub-states, and appearance of new cell sub-states (Fig 1G, Suppl Fig S1G). The lack of response is especially clear when juxtaposed to experimental autoimmune encephalomyelitis (EAE)-triggered responses performed using the same purification and sequencing protocols in the same laboratory (EAE; Fig 1G). Thus, the central effects of acute HFD are distinct from those of chronic HFD, and have little to no effect on microglial expansion, transcription, heterogeneity, or inflammation in the hypothalamus.

A deep body of literature has highlighted how cellular metabolic changes are necessary and sufficient mediators of cell-type specific function, work pioneered recently by the immunometabolism community[20]. We tested whether such changes in cellular metabolism might underpin the microglial response to acute high-fat feeding. Interestingly, mitochondrial membrane potential was increased in primary MBH microglia sorted from animals administered a 3d HFD (Mitotracker Deep Red; Fig 2A-B). Co-staining in the same samples showed no evidence of altered mitochondrial mass (Mitotracker Green; Fig 2C). This acute microglial metabolic response (aMMR) was detectable within 12 hours of high-fat feeding (Fig 2B). Importantly, aMMR appeared transient and distinct from chronic HFD contexts; parallel measures showed no induction of membrane potential in 4-week HFD animals (Fig 2B). Thus, microglia respond to acute HFD with a unique and specific acute mitochondrial metabolic response.

To understand the inputs that trigger aMMR, we performed targeted metabolomics of cerebrospinal fluid (CSF) (Fig 2D; Suppl Table 1). Overall, relatively few metabolites change upon 3d HFD. Nicotinamide-N-oxide was the only metabolite that decreased significantly; and six metabolites increased upon 3d HFD including methylmalonate, isovalerylcarnitine, nicotinic acid, glutaryl carnitine, and the fatty acids palmitate (hexadecanoic acid) and stearate (octadecanoic acid). Palmitate and stearate, the only two metabolites that changed by >2-fold, are highly enriched in the HFD itself (Research Diets D12492) suggesting that microglia respond “directly” to dietary fatty acid levels.

To test whether these observed fatty acid changes in the CSF might directly trigger aMMR, we switched to an *in vitro* primary neonatal microglia model and examined the effects of the more abundant of these, palmitate [21] (Fig S2A-B). Palmitate had no effect on either baseline or maximal oxygen consumption under standard culture conditions (Fig 2E). That said, when added in conjunction with succinate (to prime complex II-mediated OxPhos), palmitate-treated microglia were unable to utilize succinate. Acute palmitate therefore appears to rapidly compromise or saturate complex II function and prevent utilization of substrates routed through complex II. Consistent with these *in vitro* findings, fresh primary microglia from 3d HFD animals failed to respond to complex II-specific mitochondrial stimuli (Rotenone + Succinate; Fig 2F) validating the findings in adult, *ex vivo* contexts. Consistent with the *in vivo* observations above, *in vitro* palmitate exposure decreased microglial mitochondrial length within 24 hours, indicating that fatty acid exposure itself is sufficient to trigger mitochondrial fission in a cell autonomous manner (Fig 2G upper panels). This result also confirms observations by Kim *et al.* who observed mitochondrial fission and DRP1 phosphorylation upon 3d-HFD treated mice [10]. Collectively, these responses were independent of any mitoSOX-detectable ROS release (Fig S2C),




FIGURE 2

A rapid Microglial Mitochondria Response to high fat diet

A. FACS plots depicting the ratio Mitotraker Deep Red/ Mitotraker Green from sorted microglial cells of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 3 days (3-day HFD).

B. Graph showing the ratio Mitotraker Deep Red/ Mitotraker Green from sorted hypothalamic microglial cells of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 12 hours, 3 days or 1-4 weeks (n=5 to 12).

C. Graph showing the Mitotraker Green fluorescence from sorted hypothalamic microglial cells of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 12 hours, 3 days or 1-4 weeks (n=5 to 12).

D. Volcano plot showing the metabolites content of cerebrospinal fluid from of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 3 days (n=10).

E. Seahorse (+/- succinate added in the media during the experiment) on primary microglia challenged for 24 hours with BSA (control) or Palmitate (experiment replicated 3 times).

F. Mitochondrial Electron transport chain activity recorded with FACS after TMRM staining from sorted microglial cells of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 3 days (n=5).

G. Mitochondrial networks from primary microglia stained with Mitotraker green after being challenged for 24 hours with BSA (control), Palmitate, Oleate or LPS (n=40) and the mitochondrial length quantification graphs.

H. DRP1 colocalization with the mitochondrial network stained with TOMM20 on primary microglial cell after being challenged for 24 hours with BSA (control) and Palmitate (n=40) and the colocalization quantification graphs.

Data are presented as mean $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc test.

and, were associated with recruitment of the mitochondrial fission regulator DRP1 (**Fig 2H**). A 24h exposure to the mono-unsaturated fatty acid oleate failed to elicit a comparable fission response (**Fig 2G**), and, acute palmitate exposure had no effects on microglial cytokine release *in vitro* (IL6, IL1 β , TNF α ; **Fig S2E**). Thus, acute *in vitro* fatty acid exposure recapitulates *in vivo* aMMR, including selective loss of complex II activity and lack of significant inflammatory cytokine response.

aMMR is required for diet induced homeostatic rewiring *in vivo*

We tested whether mitochondrial dynamics are required for the *in vivo* metabolic responses to 3d HFD. We generated tamoxifen-inducible, microglial-*Drp1* knockout mice (*Drp1*^{MGKO}) by crossing *Drp1*^{fl/fl} animals with a Cx3cr1^{creER} transgenic line [22, 23]. *Drp1*^{MGKO} animals were born at Mendelian ratios and grow normally. Tamoxifen injection followed by 4 weeks washout generated the intended *Drp1*-deletion (**Fig 3 A-B**, **Suppl Fig 3A**) [23].

Body weight, fat mass and lean mass regulation were normal both before and after tamoxifen injection in *Drp1*^{MGKO} mice, indicating that microglial DRP1 (and by extension microglial mitochondrial fusion) is dispensable for body weight regulation under standard conditions (**Suppl Fig 3B-C**). These data are consistent with literature [24]. *Drp1*^{MGKO} mice also showed normal glucose and insulin tolerance (**Fig 3C**). Importantly, whereas 3d HFD triggered post-absorptive hyperglycemia and enhanced glucose-induced insulin release in control animals, *Drp1*^{MGKO} failed to mount a comparable whole body metabolic response (**Fig 3D**). Thus, while microglial mitochondrial dynamics are dispensable for baseline control of body weight and glucose homeostasis, they are absolutely necessary for the very earliest metabolic anomalies induced when switching to HFD. Consistent with the data from **Fig 1**, the 3d HFD-induced-hyperglycemia that is observed under overtly catabolic conditions, which we found to be microglia independent (**Fig 1C**), was still present in *Drp1*^{MGKO} animals (**Fig 3D**). These data reinforce the conclusion that the metabolic responses to acute HFD are highly specific and include both microglia-dependent and independent mechanisms. Thus, microglial mitochondrial dynamics are required for the immediate *in vivo* homeostatic response to 3d HFD.

Microglia take up and metabolize free fatty acids

Due in part to the long isolation times required to generate pure primary adult microglia, metabolite tracing experiments on primary adult microglia are not currently feasible. We therefore chose primary murine neonatal microglia as our model of choice for more mechanistic experiments [25]. Using BODIPY fluorescence as a readout, we found that primary microglia increase lipid droplet numbers within 24h of *in vitro* exposure to palmitate (200uM; **Fig 4A**), demonstrating a capacity to take up fatty acids. We therefore used stable isotopic tracer labelling and directly quantified U-[¹³C]-palmitate (¹³C-palmitate) processing in both control (BSA treated) and 24h palmitate pre-exposed microglia. Primary microglia were incubated with ¹³C-palmitate for 4 hours, washed and subjected to GCMS or LCMS-based metabolomics (**Fig 4B**). Focusing first on the control microglia we observed significant palmitate uptake and incorporation into downstream metabolites (**Fig 4C-F**; and **Fig 4O**). This is the first definitive demonstration to our knowledge that microglia metabolize fatty acids. ¹³C-palmitate label was processed to palmitoylcarnitine and acetylcarnitine indicating that microglial fatty acid metabolism acts via the canonical CPT1/CPT2 pathway, moving carbons from outside the mitochondria into the inner mitochondrial matrix (**Fig 4C**, **suppl Fig S4A**). ¹³C-labelling was also found in ¹³C-acetylserine, indicating that palmitate is processed through β -oxidation and that it contributes to the acetyl-coA pool (**Fig 4D**, **suppl Fig S4B**). Label was detected in all measured TCA cycle intermediates (**Fig 4E**, **suppl Fig S4C**). The labelling ratios of TCA intermediates and glutamate indicated that microglia push a substantial fraction of palmitate-derived carbons out of the TCA (alpha-ketoglutarate (a-KG) to glutamate) rather than processing them further through the whole TCA cycle (towards malate) (**Fig 4E-F**, **suppl Fig S4D**). Thus, microglia store and metabolize palmitate towards energy and towards a unique set of anaplerotic reactions.




FIGURE 3

aMMR is required for diet induced homeostatic rewiring *in vivo*

A. Immunostaining of TOMM20 and DRP1 on sorted microglia from mice *Drp1^{MGWT}* or *Drp1^{MGKO}*

B. Western Blot against DRP1 on sorted microglia from mice *Drp1^{MGWT}* or *Drp1^{MGKO}*

C. Graphs showing the overnight fasted glycemia, the 2hours fasted glycemia and the insulin released from *Drp1^{MGWT}* or *Drp1^{MGKO}* fed with control diet (n=5 to 11).

D. Graphs showing the overnight fasted glycemia, the 2hours fasted glycemia and the insulin released from *Drp1^{MGWT}* or *Drp1^{MGKO}* fed with 3 day high fat diet (n=5 to 11).

Data are presented as mean $\pm$ SEM. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc test.




FIGURE 4

Palmitate induces a novel microglial lactate/succinate/itaconate release pathway

A. BODIPY staining on primary microglia challenged for 24hours with BSA or palmitate and the lipid droplets quantification graph. (n=20)

B. Schematic depicting the timeline for the tracing experiments (^{13}C -palmitate or ^{13}C -glucose) on primary microglial challenged for 24hours with BSA or palmitate.

C. ^{13}C -palmitate incorporation into palmytoilcarnitine (m+16) and acetylcarnitine (m+2) after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate (n=3).

D. ^{13}C -palmitate incorporation into acetyl serine (m+2) after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate (n=3).

E. ^{13}C -palmitate incorporation into aconitate, alpha-ketoglutarate, fumarate, malate (m+2) after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate (n=3).

F. ^{13}C -palmitate incorporation into glutamate (m+2) after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate (n=3).

G. ^{13}C -palmitate incorporation into glutamate (m+2) released during the 4 hours tracing experiment by primary microglia pretreated for 24hours with BSA or palmitate (n=3). The results are graphed in relative abundance.

H. ^{13}C -palmitate incorporation into itaconate (m+1) released during the 4 hours tracing experiment by primary microglia pretreated for 24hours with BSA or palmitate (n=3).

I. ^{13}C -palmitate incorporation into succinate (m+2) released during the 4 hours tracing experiment by primary microglia pretreated for 24hours with BSA or palmitate (n=3).

J. ^{13}C -glucose incorporation into the intracellular glucose pool (m+6) after 6 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate (n=3).

K. ^{13}C -glucose incorporation into glutamate (m+2) released during the 6 hours tracing experiment by primary microglia pretreated for 24hours with BSA or palmitate (n=3).

L. ^{13}C -glucose incorporation into itaconate (m+1) released during the 6 hours tracing experiment by primary microglia pretreated for 24hours with BSA or palmitate (n=3).

M. ^{13}C -glucose incorporation into succinate (m+2) released during the 6 hours tracing experiment by primary microglia pretreated for 24hours with BSA or palmitate (n=3).

N. ^{13}C -glucose incorporation into lactate (m+3) released during the 6 hours tracing experiment by primary microglia pretreated for 24hours with BSA or palmitate (n=3).

O. Schematic depicting the metabolic pathways used by the primary microglial challenged for 24hours with BSA (black arrow) or palmitate (red arrow) during the different tracing (^{13}C -palmitate or ^{13}C -glucose).

Data are presented as mean $\pm$ SEM. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc test.

Palmitate induces a novel microglial lactate/succinate/itaconate release pathway

We next evaluated the effect of palmitate *pretreatment* on the same cellular metabolic processes. Palmitate *pretreatment* of the same neonatal primary microglia model interestingly increased labelling of palmitoylcarnitine, acetylcarnitine and acetylserine, demonstrating that 24h palmitate exposure accelerates β -oxidation (Fig 4C-D, suppl Fig S4A-B). The pre-exposure enhanced m+2 label enrichment at a-KG and glutamate without impacting other TCA intermediates (Fig 4E-F, suppl Fig S4C-D) indicating that fatty acid exposure further increases microglial substrate routing to glutamate and anaplerosis. Tracer measurements made in extracellular media conditioned from the same cells revealed that 24h palmitate treatment triggered release of glutamate, succinate, and intriguingly itaconate (Fig 4G-I), an immunomodulatory metabolite known to inhibit succinate dehydrogenase (Complex II) [26] and recently shown to be neuroprotective [27]. These findings are consistent with the complex II inhibition observed above upon 3d HFD/palmitate treatment and suggest that itaconate-dependent inhibition of complex II inhibition may be crucial in limiting the bioenergetic utilization of fatty acids by microglia, enabling their re-release and provisioning of neighboring cells. Collectively, the data demonstrate that microglia sense, process and re-release fatty acids derived carbons in the form of usable substrates (Fig 4O).

We next tested whether these effects were generalizable to other carbon substrates taken up by microglia during aMMR. We repeated the experiment, replacing U-[^{13}C]-palmitate with U-[^{13}C]-glucose (Fig 4B). Under control conditions, microglia exhibited strong glucose uptake, glycolysis and incorporation of glucose-label into TCA intermediates (Fig 4J, suppl Fig S4E). Substantial ^{13}C labelling was detected in pyruvate, citrate, a-KG, malate, and again in glutamate. These data confirm that the unexpected TCA shunt toward glutamate/glutamine pathway is a unique characteristic of the microglial metabolic fingerprint and not specific to palmitate routing. Importantly, ^{13}C -glucose-derived metabolites were also detected *extracellularly* in the form of glutamate, itaconate and succinate, as well as in extracellular lactate (m+3) (Fig 4K-N). And, palmitate pretreatment *increased* all of these signatures, including glucose uptake (Fig 4J), lactate labelling and lactate release. Interestingly, as with palmitate-tracing experiments, fatty acid pretreatment increased release of tracer-labeled itaconate and succinate into the extracellular media (Fig 4L-M). aMMR is therefore characterized by synergistic induction of a Warburg-like metabolic signature by glucose and palmitate, and significant release of carbon fuels to the cell exterior (Fig 4N). Collectively, these data identify microglia as a novel metabolic and neuroprotective node, able to take-up harmful free fatty acids and repurpose them to fuel surrounding cells in the form of lactate and anaplerotic substrates (Fig 4O).

Acute HFD induces widespread MMR and rapid modulation of spatial and learning memory

Changes in neuronal function have previously been linked to lactate provided by astrocytes [28]. To determine if the substrates released by microglia have the potential to directly influence neurons, we incubated primary neuron cultures (Suppl Fig S5A) with conditioned media from the microglial ^{13}C -glucose tracing experiments (ie. media containing ^{13}C -glucose-derived isotopically labeled lactate, itaconate, succinate, citrate). As a control for the direct uptake of ^{13}C -glucose, we treated parallel neuronal cultures with the same fresh ^{13}C -glucose tracing media originally added to the microglia. Intriguingly, and consistent with literature documenting poor direct glucose utilization by neurons [29], we found substantial m+3 lactate (as well as other metabolites) in neurons treated with microglial conditioned media, and at levels that far exceeded labelling triggered by glucose tracer alone (Fig 5A, middle column vs left column)(Suppl Fig S5B, Suppl Table 2). The data indicate higher uptake of citrate and itaconate from the control

microglia-conditioned media, further supporting the hypothesis that neuronal metabolism is reproducibly impacted by palmitate-triggered changes in microglial products. These data demonstrate that palmitate metabolism by microglia modulates neuronal carbon substrate use *in vitro*, and, they highlight the relative importance of this process compared to uptake of pure glucose. The data identify a candidate mechanism by which aMMR may alter neuronal function *in vivo*.




FIGURE 5

Acute HFD induces widespread MMR and rapid modulation of spatial and learning memory

A. Primary microglial cell media was collected after the ^{13}C -glucose tracing (containing ^{13}C -lactate released by microglia challenged with BSA or Palmitate) and incubated for 4 hours with primary neurons, the graph shows the ^{13}C -lactate incorporation in the neurons in relative abundance, as control, primary neurons were incubated directly with ^{13}C -glucose (n=6).

B. Graph showing the ratio Mitotraker Deep Red/ Mitotraker Green from sorted cortical microglial cells of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 3 days (3-day HFD) (n=5 to 12).

C. Graph showing the ratio Mitotraker Deep Red/ Mitotraker Green from sorted hippocampic microglial cells of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 3 days (3-day HFD) (n=5 to 12).

D. Graph showing the latency during the Barnes Test from mice fed with normal diet (Control) or 3 days HFD (3-day HFD) (n=11). The test was performed in the VAI animals facility (USA).

E. Graph showing the alternation during the T Maze Test from mice fed with normal diet (Control) or 3 days HFD (3-day HFD) (n=11). The test was performed in the VAI animals facility (USA).

F. Graph showing the distance walked during the ROTAROD test from mice fed with normal diet (Control or 3 days HFD (3-day HFD) (n=11).

G. Graph showing the number of turn before the mice fall during the ROTAROD test from mice fed with normal diet (Control) or 3 days HFD (3-day HFD) (n=11).

H. Graph showing the latency during the ROTAROD test from mice fed with normal diet (Control) or 3 days HFD (3-day HFD) (n=11).

I. Microglial staining with Iba1 (green) in the Hippocampus slices from mice fed with 3 days HFD or mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 prior the 3 days HFD (PLX-5662) (n=5).

J. Graph showing the latency during the Barnes Test from mice fed with normal diet (Control) (n=4), mice fed with 3 days HFD (3-day HFD) (n=6), mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 (PLX-Control) (n=8) or mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 prior the 3 days HFD (PLX-3-day HFD) (n=5).

K. Graph showing the latency during the Barnes Test from *Drp1^{MGWT}* or *Drp1^{MGKO}* mice fed with normal diet (Control diet) or with 3 days HFD (3-day HFD) (n=11).

Data are presented as mean $\pm$ SEM. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc test.

The majority of literature relating HFD-associated microglial function to metabolic regulation is focused on the hypothalamus, that exhibits an unusually leaky blood brain barrier [8, 30]. Given our findings that CSF fatty acid levels double upon acute HFD and given the dramatic metabolomic rewiring induced by microglial palmitate exposure, we asked whether aMMR might also occur in other brain regions. We FACS-sorted cortical and hippocampal microglia and tested for mitochondrial activation (MMR) in 3d HFD exposed mice. Indeed, 3d HFD exposure triggered

an increase in mitochondrial membrane potential in both cortical and hippocampal microglia (**Fig 5B-C**). These data were consistent with the CSF results and suggested therefore that acute high-fat feeding might alter higher cognitive function.

Given the hippocampal signature, we tested whether 3d HFD mice showed any deleterious memory phenotype compared to chow-fed controls. Surprisingly, HFD-treated animals outperformed the controls. Using a standard Barnes test, 3d HFD mice exhibited a faster reaction (**Fig 5D**, **Suppl Fig S7A**), suggestive of improved learning and spatial memory. Similarly, when challenged with a T-Maze, 3d-HFD exposed animals exhibited heightened spatial memory (**Fig 5E**, **Suppl S7E**). These phenotypes were reproducible at two different institutes (VAI, USA and MPI-IE, Germany) and in the hands of different experimentalists (**Fig 5D-E**, **Suppl Fig S5C-D**, **Suppl Fig S7A-B** and **S7E-F**). Notably, the memory differences were observed in the absence of any detectable changes to motor coordination (ROTAROD; **Fig 5F-H**, **Suppl S8A**). Thus, acute high-fat feeding triggers improvements in learning and spatial memory.

To validate that these 3d HFD induced cognitive effects were aMMR dependent, we once again repeated experiments in microglia-depleted (PLX-5622) and *Drp1*^{MGKO} mice. Importantly, PLX-5622-treated animals failed to show any detectable memory improvements upon a 3d HFD (**Fig 5I-J**, **Suppl S7C**) indicating indeed that an intact microglial compartment is necessary for acute HFD enhancement of memory function. Likewise, 3d HFD exposure failed to trigger memory improvements in *Drp1*^{MGKO} mice (**Fig 5K**, **Suppl S7D**) indicating that the memory enhancing response, like the glucose homeostatic effect, is microglial DRP1-dependent. Again, no mice in any treatment group showed altered motor effects by ROTAROD (**Suppl FigS5 E-J** and **Suppl S8B-C**). Therefore, the aMMR in response to 3d HFD constitutes a generalized response that couples acute dietary changes to diverse central functions.

Discussion

Our data identify a new role for microglial cells as a rapid metabolic sensor of dietary macronutrient composition, and as a relay that triggers cognitive and peripheral metabolic responses. One of the most intriguing results was the directionality of the rapid metabolic responses. Whereas a bulk of literature demonstrates adverse outcomes upon chronic HFD, both in the brain (microgliosis, inflammatory cytokine release, myeloid cell infiltration) and periphery (hyperglycemia, insulin resistance) [8, 9], our findings indicate that acute HFD initiates a distinct homeostatic response that supports cognitive function. Evolutionarily, there are obvious benefits to partitioning energy use towards cognition when energy needs are met. We propose that aMMR could result from direct uptake, processing, and release of fatty acid derived carbons, and demonstrate that microglia are capable of metabolizing fatty acids towards diverse intracellular and extracellular pools. One immediate question raised by this work is the mechanistic nature of the flip from the seemingly beneficial acute MMR (aMMR) observed here, to the well-documented inflammatory MMR (iMMR) triggered after 1-2 weeks of chronic HFD. One possibility is that the response requires flexibility between lipid storage and processing, and that this becomes saturated with prolonged HFD.

Of equal interest are the PLX5622 experiments and data, which demonstrate for the first time that microglial ablation has no overt effect on baseline metabolism and memory. Importantly, however, the data show that microglia are critical for optimal response to dietary change. We are aware of the fact that CSFR1 inhibiting compounds such as PLX5622 deplete not only microglia but also long living CNS macrophages in the meninges and perivascular space [31] but they are by far less numerous and placed far from neurons in the parenchyma. We demonstrate a novel role for microglia in optimizing glycemia upon short-(2 hours) but not long-(24 hour) term fasting and therefore suggest that microglia mediate a glucose-sparing function during the transition from post-prandial to fasted states. Future work mapping the downstream neuronal circuitry governing

this response will be important. The overabundance of food since industrialization has skewed a significant global population towards chronic prandial and post-prandial states and away from intermittent fast-feed cycles. The finding that aMMR coordinates central metabolic balance with peripheral glucose homeostasis selectively during the prandial/post-prandial phase adds nuance to a significant literature distinguishing these physiological contexts [32], [33], [34]. From an evolutionary perspective it is easy to rationalize why initial periods of plenty would be mechanistically coupled to maximizing central functions.

One question raised by these findings is if there is a hierarchy for substrate sharing between glial cells (microglia, tanycytes, oligodendrocytes and astrocytes) and neurons. Our data indicate that microglia provide several TCA-associated substrates into the extracellular milieu, and, that palmitate/HFD increases this activity. Tanycytes and astrocytes have both been documented to release select metabolites into the extracellular environment [35], [36]. The experiments presented here do not completely rule out a contribution of these or cell types in coupling acute HFD intake to memory and learning. Given that CSF production is only loosely compartmentalized (e.g. relative to the highly physically structured control of blood), we suspect a cooperative model over hierarchical, serial or synergistic metabolic compartmentalization models. Other new questions relate to the depth or breadth of other cognitive processes that might also be influenced by acute HFD. Here, we demonstrate that aMMR involves release of at least 4 important anapleurotic substrates, and that aMMR is detectable from the hypothalamus to the hippocampus and cortex. Increased lactate has been shown to enhance fear memory in a glutamate-associated mechanism ([37]). Both lactate and glutamate are increased upon 3d HFD, suggesting that aMMR may comprise a much more complex behavioral response.

In addition to identifying novel substrate routing patterns in microglia, our data demonstrate that mitochondrial fission is necessary for aMMR. Fatty acid triggered fission has been observed in several cell types [38] including neurons and glial cells [39], [40], [10]. Work by Kim et al. [10] suggests that the aMMR characterized here may require UCP2; those authors demonstrated UCP2-dependent mitochondrial changes in short- and long-term HFD exposed hypothalamic microglia. Collectively the two studies argue against astrocytes being the only cells in their ability to use fatty acids and release fatty-acid derived substrates for use by neurons and neighboring cells [41]. Studies have identified stearate and palmitate in the CSF of patients with chronic obesity and with diabetes, reports that highlight the importance of these findings [42]. While a systematic dissection of the roles of HFD-regulated CSF metabolites (direct (diet containing) and indirect (secondary)) is beyond the scope of this study, though they represent priority areas for future investigation. This is particularly true given the wide-range of fatty-acid specific biological effects in the literature, and the potential for combinatorial interactions.

Finally, this study demonstrates unappreciated plasticity and complexity in microglial cellular metabolism. Rather than being glucose-constrained, we reveal that primary microglia from across the brain readily take-up, metabolize and store fatty acids and that fatty acids are metabolized towards bioenergetic and acetylation reactions (acetyl-coA). They prove for the first time that substantial β -oxidation occurs in microglia cells even in the presence of high extracellular glucose [43]. The coordinate observations of intra- and extracellular succinate and itaconate accumulation and relative Complex II inhibition indicate that palmitate metabolism drives feed-forward inhibition of Complex II via itaconate production and shunting of TCA intermediates out of the cycle towards glutamate. Further examination of the role of glutamine as a fuel and anapleurotic regulator of cellular function is therefore warranted. At least under the standard conditions used here, microglia appear metabolically wired to also release lactate, succinate, glutamate, citrate and itaconate. The idea is consistent with the observed lack of substantial intracellular lipid accumulation, respiration, or ROS buildup upon prolonged palmitate exposure. Such substrate release could mediate the learning and memory effects that accompany aMMR; they are consistent with the data of other studies that have examined metabolite associations with learning and memory [44–47].

Acknowledgements

We thank Karsten Hiller, Thekla Cordes, Heidi Lempradl, Connie Krawczyk and Mylène Tajan for critical input and theoretical discussions. We thank Alexis Bergsma for technical support. We are indebted to the MPI-IE facilities and the VAI Vivari and facilities including the metabolomics, imaging, and genomics cores. This work was supported by funding from the MPG, the VAI, the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 675610, the NeuroMac CRC/TRR167 and the Marie Skłodowska-Curie Postdoctoral Fellowship (EPOC – 707123). The team is supported by National Institutes of Health awards R21HG011964 and 1R01HG012444.

Material and methods

Experimental Animals

All animal studies and experimental procedures were approved by either the Max Planck Committees in Germany or by the Van Andel Institute Institutional Animal Care and Use Committee in US, before project initiation. All mice were housed in a temperature-controlled environment (23°C) with a 12-h light and 12-h dark (07.00–19.00) photoperiod. Animals were provided standard chow diet (Research Diets #5021; 23,6% calories from fat; Mouse Breeder Diet #6539) or HFD (60% fat; Research diet, Rodent Chow #D12492) and water ad libitum unless otherwise stated.

For the experiments performed on non-modified mice, C57BL/6J were purchased from Jackson Laboratory. *Drp1* floxed mice (*Drp1^{fl/fl}*) and *Cx3cr1^{CreER}* mice (B6.129P2(C)-*Cx3cr1^{tm2.1(cre/ERT2)Jung/J}*) were purchased from Jackson Laboratory. Mice expressing tamoxifen-inducible Cre recombinase (CreERT2) in cells expressing CX3CR1 (*Cx3cr1-cre:ERT2*) were crossed with mice harboring conditional alleles *Drp1* (*Drp1^{fl/fl}*). For induction of Cre recombinase, 5- to 6-week-old *Drp1^{MGKO}* (*Drp1^{fl/fl}-Cx3cr1-cre*) mice and their littermate control, were treated with 4 mg tamoxifen (TAM, Sigma) solved in 200 µl corn oil (Sigma) injected subcutaneously at two time points 48 h apart. High fat diet (HFD) was started 4 weeks from the last injection to allow the replacement of peripheral monocytes [22]. Mice were sacrificed at different time points during the diet. Only males were used in this study.

Microglial Depletion

Microglia were depleted in all cases by feeding mice custom diet (Research Diets) containing the CSF1R inhibitor PLX5622 (Plexxikon) formulated in the exact diets indicated above. The compound-containing diets have the new order numbers (D12450: PLX5622-containing standard diet and D21021905: PLX5622-containing high-fat diet). PLX5622 was included to achieve a dose of 1.2 g/kg based on average adult C57BL/6J food intake. Animals were administered PLX5622-containing diet for 7-9 days without observable impact on the body weight or food intake (Suppl Fig S6A-B), using protocols adopted from [19, 48].

Microglia Cultures

Eight to ten mice (1–3 days old, mixed sex) from C57BL/6J mice were used for primary microglia culture. In brief, brains were dissected and placed in a small culture dish that contained a small volume of Dulbecco's modified eagle medium (DMEM). The meningeal lining (dura and arachnoid layers) were then gently removed using two small straight forceps under a magnifying glass. The cleaned brain was then placed in a new culture dish minced into a fine slurry using a pair of corneal scissors. Suspended cells were filtered (70 µm) and centrifuged for 5 min at 1000 rpm and

the pellet was re-suspended and plated on poly-D-lysine (Cat# P6407, Sigma)-coated 75cm² flasks with DMEM containing 1% penicillin-streptomycin, 10% fetal bovine serum. Seven to 10 days later, the flasks were stimulated for 3 days with 30ng/ml M-CSF (Cat# 315-02, Peprotech) and then, shaken (200 rpm) for 3 hours (37°C) to specifically release microglia.

For conditioned media experiments, microglial cells were incubated with DMEM (Gibco) without lactate completed with BSA-conjugated palmitate or Control BSA. Conditioned media was collected after the incubation, centrifuged 15min at 300g (4°C) and the supernatant transferred and frozen in a fresh tube avoiding the cells and debris pellet. Sample were immediately snap frozen or use for the neurons incubation.

Embryonic Cortical Neuron Culture Protocol

Primary neuron cultures were prepared from embryonic day 18 (E18) CD1 mice. Brains were gently removed from the embryos and placed into a petri dish filled with ice cold, sterile Hibernate Medium (Cat#. A1247601, Gibco). Hemispheres were gently separated, and the meninges, thalamus, striatum, brainstem, and hippocampus were removed. Cortical tissue was isolated and cut into 1 mm³ segments. The cortical tissue from each brain was pooled and digested in papain solution (20 U/mL Cat# LS003126, Worthington) and then treated with DNase I (Cat# LS006563, Worthington) to remove residual DNA. The tissue was then washed with pre-warmed Neurobasal media (Cat# 21103049, Gibco), mechanically dissociated, and strained through a 40 µm cell strainer. The cell suspension was pelleted at 1000 rpm for 5 minutes, resuspended in 2 mL of neuron media (Neurobasal media containing 1% B27, 2mM GlutaMAX and penicillin-streptomycin) and gently mixed. The dissociated neurons were seeded on poly-D-lysine coated 6 well culture plates at 1 million cells/ well. On DIV3, cytosine arabinoside (1-β-D-arabinofuranosylcytosine) was added to a final concentration of 5 µM to curb glial proliferation. The neurons were maintained until DIV21 by replacing 1/3 volume of media with fresh neuron media every five days.

Microglia Isolation

Mice were anesthetized and blood was collected by ventricular puncture. Mice were then perfused with phosphate-buffered saline (PBS). For microglia isolation, the hypothalamus, cerebellum, hippocampus, and cortex were dissected from the brain and manually dissociated in HBSS buffer. A cell suspension was prepared with a continuous 37% Percoll gradient at 2300 rpm for 30 min without brake, then cells were washed with 1x PBS and resuspended in FACS buffer and non-specific binding to Fc receptors was blocked by incubation with anti-CD16/32 antibody (BD Pharmingen, Cat# 553141) and the FACS antibodies BV711 conjugated anti-CD11b and Pacific blue conjugated anti-CD45 antibodies (Cat# 101241, Cat# 103126, BioLegend).

Single-cell RNA-sequencing (ScRNA-seq)

For the single-cell RNAseq experiments, pure hypothalamic microglia cells were sorted and processed as previously described [49, 50].

Briefly, brains were isolated and gently homogenized and resuspended in 20 ml of ice-cold extraction buffer (1x HBSS, 1% fetal calf serum, 1 mM EDTA). Microglial cells were extracted in 5 ml of 37% isotonic Percoll. After staining, single CD45^{lo}, CD11b⁺ microglial cells were FACS-sorted directly in 192-well plates, containing 192 unique barcodes, for scRNA-seq. The CEL-Seq2 method was used for single cell sequencing [51, 52]. Thirteen libraries (2492 single cells) were sequenced on an Illumina HiSeq 2500 system, as pair-end multiplexing run, with 50-75 bp read length.

scRNA-seq analysis

The scRNA-seq libraries were analyzed using the ‘scRNAseq’ module from snakePipes v.1 [53]. Within the snakePipes pipeline, trimming of barcodes was achieved using Cutadapt v.1.9.1 [54]. Quality of the reads was evaluated with FastQC (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Mapping to the GRCm38/mm10 mouse genome was performed using the STAR aligner v.2.5.3a [55], and read counts on features were quantified by featureCounts v.1.6.1 [56]. Mapped and counted read were next analyzed with RaceID3 v.0.2.6, with default parameters [52, 57]. Batch correction by plate, and preprocessing of data were completed within the RaceID3 pipeline. We included in our analysis, all microglia cells from control (CT) and 3-day high fat diet treated (3d_HFD) mice. We filtered out all the cells with a total transcript count per cell >1000. Dimensional reduction of transcriptomic profiles was then performed with Uniform Manifold Approximation and Projection (UMAP). As a comparative analysis, we also added to our dataset, previously published single microglial cells from experimental autoimmune encephalomyelitis (EAE), and matched controls mice (CT_EAE) [42].

Data availability

The scRNA-seq raw data, processed count matrices and related metadata have been deposited to Gene Expression Omnibus (GEO) and are publicly available under the accession codes GSE217045.

qPCR

For the qPCR experiments, pure microglia cells were sorted, and the RNA was extracted with Trizol (ImGen protocol).

	Foward	Reverse
Tmem119	GTGTCTAACAGGCCCCAGAA	AGCCACGTGGTATCAAGGAG
P2ry12	CAAGGGGTGGCATCTACCTG	AGCCTTGAGTGTTTCTGTAGGG
Arg1	GGAAATCGTGGAAATGAG	CAGATATGCAGGGAGTCACC
S100B	AACAACGAGCTCTCTCACTTCC	CTCCATCACTTTGTCCACCA
RPL19	GAAGGTCAAAGGGAATGTGTTCA	CCTTGTCTGCCCTTCAGCTTGT

Mitochondrial Function by Cytometry

For the mitochondrial activity experiments, the cell suspension was incubated with the mitochondrial probes MitoTracker Green FM (Invitrogen, Cat# M7514) and MitoTracker DeepRed FM (Invitrogen, Cat# 22426) for 30min at 37degrees before FACS acquisition.

For the electron transport chain experiments (ETC), the experiment was based on the Salabei et al publication [58].

The cell suspension was incubated with the mitochondrial probe Tetramethylrhodamine TMRM 10mM (Abcam, Cat# ab228569) for 30min at 37degrees before FACS acquisition. For challenging the ETC, the cell pellet was resuspended in 500ul of warm MAS buffer solution [58] + 1nM Plasma Membrane Permeabilizer (Agilent Seahorse XF PMP) to permeabilize the cells. Microglial cells were gated from CD45low-CD11b+ cells followed by singlet after forward and side scatter pattern. They were incubated each 90 seconds by the following drugs: 0,5ul of 100uM Rotenone (Sigma), 2ul of 2.5M Succinate ph 7.4 (succinic acid Sigma) and 0.5ul of 1mM Antimycin (Sigma). Cytometry was performed on Fortessa (BD Bioscience) and analyzed with FlowJo v 10 (Treestar). Microglial cells were gated from CD45low-CD11b+ cells followed by singlet after forward and side scatter pattern.

Confocal Microscopy Analysis

Mice were anesthetized and transcardially perfused with 0.9% saline followed by fixative (4% paraformaldehyde). Brains were incubated 24 hours with the fixative, then 48 h with 20% sucrose and finally fixed with Polyfreeze (Sigma). Frozen brains were sliced into 7 μ m and incubated in 0.1% PBST + 5% BSA with anti-Iba1 antibody (diluted 1:300, Abcam; Cat#ab178846) and/or anti-GFP antibody (diluted 1:200, Cell signaling; Cat#2255), or anti-DRP1 antibody (diluted 1:50 Cell signaling; Cat#8570). After several washes with PBS, sections were incubated in the appropriated secondary antibodies (thermofisher) for 1 hr at room temperature, then rinsed in PBS three times 10 min each time, and flat-embedded in mounting media with DAPI (Fluoroshield, Abcam; Cat#104139).

For the colocalization experiment, microglia were isolated from 10- to 12-week-old drp1ko mice and their littermate controls, immediately fixed in PFA and stained with DRP1 (diluted 1:50 Cell signaling; Cat#8570) and tomm20 antibodies (diluted 1:1000, SantaCruz; Cat#sc177615). The Pictures acquisition were performed with the Confocal LSM780 (Zeiss).

Glucose and Insulin Tolerance

OGTTs were performed in 16 hours fasted animals. After determination of basal blood glucose levels, each animal received a gavage of 1g/kg glucose (Sigma) and blood glucose levels were measured at -30, 0, 15, 30, 45, 60, 90 and 120 min after glucose administration using a glucometer (Accu-Check, Roche). In the same cohort of mice, blood samples were also collected for determination of circulating insulin levels during the OGTT at -30, 15, 30 and 60 with the Elisa insulin assay kit (Mercodia).

ITTs were performed in 2 hours fasted animal. After determination of basal blood glucose levels, each animal received an i.p. injection of Insulin, 0.75 U/kg (Actrapid, Novo Nordisk). Blood glucose levels were measured at -30, 0, 15, 30, 45, 60, 90 and 120 min after insulin administration.

Body Composition

Body composition was measured in vivo by MRI (EchoMRI; Echo Medical Systems, Houston, TX).

Behavioral Tests

Mice were fasted at 7:00 AM and the behavioral tests were performed between 8:00 AM and 2:00 PM. ROTAROD, Barnes and T Maze behavioral tests were performed as previously described [59] [60].

Microglial Analysis

To analyze microglial number and size in the ARC, VMH and cortex, tdTomato positive cells were counted manually from 4 hypothalamic level-matched sections per animal using ImageJ software and microglia cell size was measured using a thresholding parameter on ImageJ software. A total of 40 cells per section were used to determine the size in all regions.

Measures of Mitochondrial length

Primary microglial cells were seeded overnight in Poly-D-lysine-coated cell culture chambered coverslips (Lab-Tek Cat#155411, Thermo scientific) at 1×10^4 cells/well density in 100 μ l microglial growth media. Then, they were incubated at 37 for 2, 6 or 24 hrs in microglial growth media completed with 100 μ M BSA or 100 μ M Palmitate complexed with BSA [25] or 100 μ M Oleate complexed with BSA or 1 μ g/ml LPS [61]. Half hour before the end of the incubation, 200 nM

MitoTrackerGreen (Invitrogen, Cat# M7514) was added in the media. The cells were washed 3 times with their own incubation media and the mitochondrial network was observed in vivo cells with Confocal LSM 780 (Zeiss).

After pictures acquisition, 5uM MitoSox (Invitrogen, Cat# M36008) were added in the incubated media for 10min. Cells were washed 3 times with media and fixed with 4%PFA at 37 for 15min. The ROS staining was observed with Confocal LSM 780 (Zeiss).

After pictures acquisition, cells were permeabilized with 0.2%Triton in PBS, incubated with blocking buffer (PBS + 5%FCS +0,1%Tween) for 1 hour and stained with anti-Iba1 antibody (diluted 1:300, Abcam; Cat#ab178846) and/or anti-TOM20 antibody (diluted 1:1000, SantaCruz; Cat#sc177615) or/and anti-DRP1 antibody (diluted 1:50 Cell signaling; Cat#8570). After several washes with PBS, sections were incubated in the appropriated secondary antibodies (thermofisher) for 1 hour at room temperature, then rinsed in PBS three times 10 min each time, the pictures acquisition were performed with the Confocal LSM780 (Zeiss).

Cytokine measurement

Media from primary Microglia incubated with BSA or Palmitate was collected and processed using the mouse Custom Panel Standard kit (#93976 LegendPlex)

Seahorse measurement

Primary Microglia were incubated with BSA or Palmitate conjugated to BSA (Agilent Seahorse Palmitate-BSA conjugation protocol) for 24h then incubated in the Seahorse XF media (+/- 0.25mM succinate) and processed using the Cell Mito Stress Test Kit (#103015 Agilent).

Stable isotope labeling and metabolomics

Metabolomics was performed on microglia by first washing microglia primary cell cultures with PBS and re-cultured in DMEM (lacking glucose) containing 10% dialyzed FBS and uniformly labeled [^{13}C]-Glucose (Cambridge Isotope Laboratories). Microglia (2×10^6 per well in 6 well plates) were cultured in ^{13}C -containing medium for up to 6 hours. For cellular media samples, 10 μL of media were taken at indicated time points and centrifuged to remove cells, with 10 μL of media used for metabolite analysis. For uniformly labeled [^{13}C]-Palmitate tracing analysis, sodium [^{13}C]-Palmitate was conjugated to BSA following Agilent Seahorse Palmitate-BSA conjugation protocol. For [^{13}C]-Palmitate tracing, microglia primary cell cultures were first cultured for 24hr with BSA control or ^{12}C -Palmitate (200uM) in DMEM containing 10% dialyzed FBS. Following 24hr incubation, the media was removed, and microglia cells washed with PBS followed by culture in DMEM with 10% dialyzed FBS and blank mM [^{13}C]-Palmitate for 4 hours and cell and media samples collected as before.


For Gas chromatography coupled to mass spectrometry (GC-MS) metabolites were extracted using ice cold 80% methanol, sonicated, and then D-myristic acid was added (750ng/sample) as an internal standard. Dried samples were dissolved in 30 μL methoxyamine hydrochloride (10mg/ml) in pyridine and derivatized as tert-butyldimethylsilyl (TBDMS) esters using 70 μL N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) [62]. For metabolite analysis, an Agilent 5975C GC/MS equipped with a DB-5MS+DG (30 m x 250 μm x 0.25 μm) capillary column (Agilent J&W, Santa Clara, CA, USA) was used. All data were collected by electron impact set at 70 eV. A total of 1 μL of the derivatized sample was injected in the GC in splitless mode with inlet temperature set to 280°C, using helium as a carrier gas with a flow rate of 1.5512 mL/min (rate at which myristic acid elutes at 17.94 min). The quadrupole was set at 150°C and the GC/MS interface at 285°C. The oven program for all metabolite analyses started at 60°C held for 1 min, then increased at a rate of 10°C/min until 320°C. Bake-out was at 320°C for 10 min. Sample data were acquired both in scan (1-600 m/z) modes. MassHunter software (v10, Agilent Technologies) was

used for peak picking and integration of GCMS data. Peak areas of all isotopologues for a molecular ion of each metabolite were used for mass isotopomer distribution analysis using a custom algorithm developed at VAI. Briefly, the atomic composition of the TBDMS-derivatized metabolite fragments (M-57) was determined, and matrices correcting for natural contribution of isotopomer enrichment were generated for each metabolite. After correction for natural abundance, a comparison was made between non-labeled metabolite abundances (^{12}C) and metabolite abundances which were synthesized from the ^{13}C tracer. Metabolite abundance was expressed relative to the internal standard (D-myristic acid) and normalized to cell number.

For liquid chromatography coupled to mass spectrometry (LC-MS) metabolites were analyzed for relative abundance by high resolution accurate mass detection (HRAM) on two QExactive™ Orbitrap mass spectrometers (Thermo Fisher Scientific) coupled to Thermo Vanquish liquid chromatography systems. Separate instruments were used for negative and positive mode analysis. For negative mode analysis, an Acquity T3 HSS (1.8 μm , 2.1 mm x 150 mm) column (Waters, Eschborn, Germany) was used for chromatographic separation and the elution gradient was carried out with a binary solvent system. Solvent A consisted of 3% methanol, 10 mM tributylamine, and 15mM acetic acid in water (pH 5.0 $\pm$ 0.05) and solvent B was 100% methanol. A constant flow rate of 200 $\mu\text{L min}^{-1}$ was maintained and the linear gradient employed was as follows: 0–2.5 min 100% A, 2.5–5 min increase from 0 to 20% B, 5–7.5 min maintain 80% A and 20% B, 7.5–13 min increase from 20 to 55% B, 13–15.5 min increase from 55 to 95% B, 15.5–18.5 min maintain 5% A and 95% B, 18.5–19 min decrease from 95 – 0% B, followed by 6 min of re-equilibration at 100% A. The heater temperature was set to 400° C and ion spray voltage was set to 2.75 kV. The column temperature was maintained at 25 °C and sample volumes of 10 μL were injected. A 22-minute full-scan method was used to acquire data with m/z scan range from 80 to 1200 and resolution of 70,000. The automatic gain control (AGC) target was set at 1e6 and the maximum injection time was 500 ms. For positive mode analysis, an Atlantis T3 (3 μm , 2.1mm ID x 150mm) column (Waters) was used and the elution gradient was carried out with a binary solvent system Solvent A consisted of 0.1% acetic acid and 0.025% heptafluorobutyric acid in water and solvent B was 100% acetonitrile. A constant flow rate of 400 $\mu\text{L min}^{-1}$ was maintained and the linear gradient employed was as follows: 0–4 min increase from 0 to 30% B, 4–6 min from 30 to 35% B, 6–6.1 min from 35 to 100% B and hold at 100% B for 5min, followed by 5 min of re-equilibration. The heater temperature was set to 300° C and the ion spray voltage was set to 3.5 kV. The column temperature was maintained at 25 °C and sample volumes of 10 μL were injected. An 11-minute full-scan method was used to acquire data with m/z scan range from 70 to 700 and resolution of 70,000. The automatic gain control (AGC) target was set at 1e6 and the maximum injection time was 250 ms. Instrument control and acquisition was carried out by Xcalibur 2.2 software (Thermo Fisher Scientific). Full scan LC-MS data were analyzed in Compound Discoverer (v 3.2, Thermo Scientific). Compounds were identified by chromatography specific retention time of external standards and MS^2 spectral matching using the mzCloud database (Thermo Scientific).

Quantification and Statistical Analysis

Two-way ANOVA was used to determine the effect of the genotype and treatment with the Prism 7.01 software (GraphPad Software). For repeated measures analysis, ANOVA was used when values over different times were analyzed. When only two groups were analyzed, statistical significance was determined by an unpaired Student's t-test. A value of $p < 0.05$ was considered statistically significant. All data are shown as mean $\pm$ SEM unless stated otherwise. We did not include additional statistical tests for data distributions.



SUPPL FIGURE 1


Acute HFD-induced metabolic changes are microglia dependent

- A.** Graphs showing the Glucose Tolerance Test (OGTT) and the associated-insulin kinetic of C57Bl6/J male before keeping them with a control diet (Control) or before feeding them with high fat diet for 3 days (3-day HFD) (n=8).
- B.** Graph showing the Insulin Tolerance Test (ITT) of C57Bl6/J male before keeping them with a control diet (Control) or before feeding them with high fat diet for 3 days (3-day HFD) (n=5).
- C.** Graphs showing the Glucose Tolerance Test (OGTT) expressed in percentage from the basal glycemia of C57Bl6/J male fed with a control diet (Control) or fed with high fat diet for 3 days (3-day HFD) (n=8).
- D.** Graph showing the body weight evolution between C57Bl6/J male fed with control diet (Control) or fed with high fat diet for 3 days (3-day HFD), before and after the diet change. (n=7).
- E.** IBA1 immunostaining on hypothalamic slices from C57Bl6/J male fed with control diet (Control) or fed with high fat diet for 3 days (3-day HFD) and its quantification (n=10).
- F.** IBA1 and YFP immunostaining on hypothalamic slices from Cx3cr1creERT2-Rosa26YFP mice fed with control diet or 3 days high fat diet for 3 days (n=5).
- G.** sgRNAseq dataset from hypothalamic microglia cells harvested from C57bl6/J male mice fed with control diet (Control) and High Fat Diet for 3 days (HFD_3d) (n=5)

Data are presented as mean $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc.

<i>Metabolite</i>	<i>FC</i>	<i>log2FC</i>	<i>P.value</i>	<i>log10.P.Value</i>	<i>Enrichment</i>
KynurenicAcid	3.56	1.83	0.24	0.62	Not Sig
HexadecanoicAcid	2.27	1.18	0.01	2.11	HFD 3d
Nicotinamide-N-oxide	0.45	-1.14	0.02	1.71	CT
OctadecanoicAcid	2.17	1.12	0.02	1.64	HFD 3d
Serotonin	0.51	-0.98	0.95	0.02	Not Sig
N-Methyl-4-Pyridone-3-Carboxamide	1.81	0.85	0.06	1.21	Not Sig
Methylmalonate	1.80	0.85	0.01	1.86	Not Sig
TetradecanoicAcid	1.78	0.83	0.29	0.53	Not Sig
Octanoylcarnitine	0.60	-0.73	0.99	0.00	Not Sig
Propionylcarnitine	1.65	0.73	0.45	0.35	Not Sig
Isovalerylcarnitine	1.65	0.72	0.02	1.74	Not Sig
NicotinicAcid	1.60	0.68	0.04	1.39	Not Sig
Glutaryl carnitine	1.60	0.68	0.00	2.40	Not Sig
Nicotinamide	0.63	-0.66	0.07	1.13	Not Sig
1-methylnicotinamide	0.66	-0.59	0.31	0.51	Not Sig
OphthalmicAcid	0.68	-0.56	0.24	0.62	Not Sig
N-methylserotonin	1.41	0.49	0.17	0.77	Not Sig
O-Acetylcarnitine	1.38	0.47	0.62	0.21	Not Sig
Tryptophan	1.35	0.43	0.10	1.02	Not Sig
3-hydroxyanthranillicAcid	1.34	0.43	0.20	0.69	Not Sig
Butyrylcarnitine	1.33	0.42	0.28	0.55	Not Sig
Nudifloramide	1.27	0.34	0.04	1.41	Not Sig
QuinolinicAcid	1.21	0.27	0.22	0.66	Not Sig
S-Adenosyl-L-Homocysteine	0.84	-0.26	0.44	0.35	Not Sig
Isobutyrylcarnitine	1.15	0.21	0.62	0.20	Not Sig
2-MethylbutyrylCarnitine	1.15	0.20	0.64	0.19	Not Sig
NicotinicAcidMononucleotide	0.90	-0.15	0.33	0.49	Not Sig
Hexanoylcarnitine	1.10	0.14	0.69	0.16	Not Sig
NicotinamideMononucleotide	1.10	0.14	0.95	0.02	Not Sig
Carnitine	1.06	0.08	0.88	0.06	Not Sig
S-Adenosyl-L-Methionine	1.06	0.08	0.61	0.21	Not Sig
3-Hydroxykynurenine	1.04	0.06	0.87	0.06	Not Sig
NicotinuricAcid	0.96	-0.06	0.64	0.19	Not Sig
AnthranillicAcid	1.04	0.05	0.96	0.02	Not Sig

TABLE_1



SUPPL FIGURE 2

A rapid Microglial Mitochondria Response to high fat diet

A. IBA1 immunostaining of primary microglia cells treated with BSA (control) or Palmitate for 24hours.


B. Graph showing mRNA expression of microglial marker (TMEM119) or astrocytes marker (S100B) or macrophages marker (Arg1) in primary microglial culture challenged for 24hours with BSA or palmitate. Primary culture of astrocytes and macrophages were used as positive controls.

C. MitoSOX staining of primary microglial cells after being challenged for 24hours with BSA (control), Palmitate, Oleate or LPS (n=10) and the MitoSOX quantification graph.

D. Mitochondrial networks from primary microglia stained with Mitotraker green and stained with MitoSOX after being challenged for 2hours with BSA (control), Palmitate, Oleate or LPS (n=40) and the mitochondrial length as well as the MitoSOX quantification graphs

E. Interleukins concentrations (TNFalpha, IL-1beta, IL6) in the primary microglia cells media after being challenged for 24hours with BSA or palmitate (n=7)


Data are presented as mean $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc.



SUPPL FIGURE 3

aMMR is required for diet induced homeostatic rewiring *in vivo*

A Schematic depicting the timeline for the tamoxifen injection and the experiments performed on *Drp1*^{MGWT} or *Drp1*^{MGKO} **A**.
B. Graph showing the body weight evolution among all the *Drp1*^{MGKO} genotypes after the tamoxifen injection (n=6 to 11)
B. Graphs showing the fat mass and lean mass evolution among all the *Drp1*^{MGKO} genotypes after the tamoxifen injection (n=6 to 11)
C. Graphs showing the body weight before and after the 3 day HFD for the mice *Drp1*^{MGWT} and *Drp1*^{MGKO} (n=11 to 13)
 Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc.



SUPPL FIGURE 4


Palmitate induces a novel microglial lactate/succinate/itaconate release pathway

A ^{13}C -palmitate incorporation into palmytoilcarnitine and acetylcarnitine after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate ($n=3$). The results are graphed in relative abundance. **A. B.** ^{13}C -palmitate incorporation into acetyl-serine after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate ($n=3$). The results are graphed in relative abundance.

B. ^{13}C -palmitate incorporation into aconitate, alpha-ketoglutarate, fumarate, malate after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate ($n=3$). The results are graphed in relative abundance.

C. ^{13}C -palmitate incorporation into glutamate after 4 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate ($n=3$). The results are graphed in relative abundance.

D. ^{13}C -glucose incorporation into pyruvate, citrate, alpha-ketoglutarate, succinate, and malate after 6 hours tracing experiment on primary microglia pretreated for 24hours with BSA or palmitate ($n=3$). The results are graphed in pool size. Data are presented as mean $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc.



SUPPL FIGURE 5

Acute HFD induces widespread MMR and rapid modulation of spatial and learning memory

A. Map2, NeuN, Iba1 and Map2, NeuN, GFAP immunostainings on primary neurons.

B. Primary microglial cell media was collected after the ^{13}C -glucose tracing (containing ^{13}C -metabolites released by microglia challenged with BSA or Palmitate) and incubated for 4 hours with primary neurons, the graph shows the ^{13}C -citrate, ^{13}C -itaconate and ^{13}C -succinate incorporation in the neurons in relative abundance (n=6).

C. Graph showing the latency during the Barnes Test from mice fed with normal diet (Control), or 3 days HFD (3-day HFD) (n=11). The test was performed in the MPI animals facility (Germany).

D. Graph showing the alternation during the T Maze Test from mice fed with normal diet (Control), or 3 days HFD (3-day HFD) (n=11). The test was performed in the MPI animals facility (Germany).

E. Graph showing the distance walked during the ROTAROD test from mice fed with normal diet (Control) (n=4), mice fed with 3 days HFD (3-day HFD) (n=6), mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 (PLX-Control) (n=8) or mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 prior the 3 days HFD (PLX-3-day HFD) (n=12).

F. Graph showing the number of turns before the mice fall during the ROTAROD test from mice fed with normal diet (Control) (n=4), mice fed with 3 days HFD (3-day HFD) (n=6), mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 (PLX-Control) (n=8) or mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 prior the 3 days HFD (PLX-3-day HFD) (n=12).


G. Graph showing the latency during the ROTAROD test from mice fed with normal diet (Control) (n=4), mice fed with 3 days HFD (3-day HFD) (n=6), mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 (PLX-Control) (n=8) or mice depleted from their microglial cells with 1 week control diet complexed with PLX-5662 prior the 3 days HFD (PLX-3-day HFD) (n=12).

H. Graph showing the distance walked during the ROTAROD test from *Drp1*^{MGWT} or *Drp1*^{MGKO} mice fed with normal diet (Control diet), or 3 days HFD (3-day HFD) (n=11).

I. Graph showing the number of turns before the mice fall during the ROTAROD test from *Drp1*^{MGWT} or *Drp1*^{MGKO} mice fed with normal diet (Control diet), or 3 days HFD (3-day HFD) (n=11).

J. Graph showing the latency during the ROTAROD test from *Drp1*^{MGWT} or *Drp1*^{MGKO} mice fed with normal diet (Control diet), or 3 days HFD (3-day HFD) (n=11).

Data are presented as mean $\pm$ SEM. *p<0.05, **p<0.01, ***p<0.001 as determined by two-tailed Student's test and two-way ANOVA followed by Bonferroni post hoc.



SUPPL FIGURE 6

A. Graph showing the body weight evolution between mice fed with normal diet or control diet complexed with PLX-5662 for 7days, prior the 3 days normal diet or 3days HFD. The 4 groups are the following :Control diet (ND)(n=6), 3days HFD (HFD) (n=8), 7day-PLX-5662 then control diet (PLX-ND) (n=12), 7day-PLX-5662 then 3-day HFD (PLX-HFD) (n=12).


B. Graph showing the food intake evolution between mice fed with normal diet or control diet complexed with PLX-5662 for 7days, prior the 3 days normal diet or 3days HFD. The 4 groups are the following :Control diet (ND)(n=6), 3days HFD (HFD) (n=8), 7day-PLX-5662 then control diet (PLX-ND) (n=12), 7day-PLX-5662 then 3-day HFD (PLX-HFD) (n=12).

Characteristic	N	Overall, N = 12 ¹	BSA, N = 6 ¹	PA, N = 6 ¹	p-value ²	q-value ³
b_DL.Lactic.Acid	12	7,768,093,932.0 (566,966,988.5)	7,315,358,105.8 (237,880,097.3)	8,220,829,758.2 (398,345,524.3)	0.002	0.064
b_D_Glutamine	12	92,514,878.8 (9,477,866.2)	99,910,567.8 (6,363,882.4)	85,119,189.7 (5,084,875.9)	0.002	0.064
a_Acetyl.L.carnitine	12	21,534,366.5 (5,136,659.2)	25,486,005.2 (4,313,399.0)	17,582,727.8 (1,401,821.0)	0.004	0.085
b_L.Serine	12	8,927,932.4 (1,999,447.4)	10,439,581.3 (1,620,380.1)	7,416,283.5 (827,833.2)	0.009	0.13
b_X4.Oxoproline	12	5,158,697.7 (2,093,379.7)	6,584,223.3 (1,496,000.9)	3,733,172.0 (1,589,279.7)	0.026	0.3
b_X3.Hydroxy.2.methyl.4.pyrone.tent.	12	112,324,855.5 (18,985,842.0)	122,558,080.8 (13,194,171.3)	102,091,630.2 (19,173,036.1)	0.065	0.6
a_Adipic.acid.tent.	12	463,554.3 (1,036,466.7)	0.0 (0.0)	927,108.7 (1,359,286.8)	0.074	0.6
a_D_.Pyroglutamic.Acid	12	287,577,957.7 (32,240,216.1)	302,927,531.8 (25,661,286.0)	272,228,383.5 (32,600,385.7)	0.093	0.6
b_L.Arabinose.or.isomer.	12	427,996,608.9 (18,980,682.8)	437,653,974.3 (18,029,045.8)	418,339,243.5 (15,611,025.3)	0.093	0.6
b_L.Tyrosine	12	85,928,933.3 (296,055,668.3)	345,898.5 (293,093.1)	171,511,968.0 (418,627,435.0)	0.13	0.7
b_Sodium.lauryl.sulfate	12	22,598.3 (76,220.7)	0.0 (0.0)	45,196.5 (107,496.4)	0.2	0.7
b_Tridecanoic.acid	12	113,734.1 (302,240.1)	0.0 (0.0)	227,468.2 (412,217.0)	0.2	0.7
a_Leucine	12	27,980,174.9 (7,729,502.5)	30,862,636.3 (2,851,217.9)	25,097,713.5 (10,167,075.1)	0.2	0.7
b_Glutaric.acid.tent.	12	440,497,616.4 (19,061,443.4)	448,877,445.2 (22,010,672.2)	432,117,787.7 (12,097,256.5)	0.2	0.7
a_PEG.n5.tent.	12	344,189.2 (776,660.6)	4,541.3 (11,123.9)	683,837.0 (1,024,721.6)	0.2	0.7
a_L.Serine	12	390,966.4 (346,737.4)	527,905.0 (409,596.4)	254,027.8 (227,430.6)	0.2	0.7
b_D_.Glucose.or.isomer.	12	5,354,625,351.9 (372,775,074.5)	5,219,148,234.7 (282,140,339.8)	5,490,102,469.2 (426,687,091.4)	0.2	0.7
b_AICA.ribonucleotide	12	64,660,392.8 (5,188,450.2)	63,405,196.7 (3,409,871.4)	65,915,588.8 (6,619,333.0)	0.2	0.7
b_neuraminic.acid.tent.	12	23,066,967.0 (2,864,562.7)	24,475,099.5 (3,412,576.8)	21,658,834.5 (1,283,781.1)	0.2	0.7
a_Betaine	12	3,612,697.5 (2,636,694.6)	2,762,143.5 (2,827,681.0)	4,463,251.5 (2,358,539.4)	0.3	>0.9
a_DL.Arginine	12	3,821,072.9 (7,222,808.1)	2,199,664.0 (5,388,054.4)	5,442,481.8 (8,912,410.1)	0.3	>0.9
b_L.Threonine	12	5,270,710.2 (5,478,082.2)	6,513,108.5 (5,492,782.8)	4,028,311.8 (5,669,696.2)	0.4	>0.9
a_Pantothenic.acid	12	22,359,057.0 (26,015,488.1)	28,020,428.8 (25,119,049.5)	16,697,685.2 (27,947,862.2)	0.4	>0.9
b_L.Leucine	12	6,646,608.2 (3,705,017.3)	7,399,027.0 (3,879,174.6)	5,894,189.3 (3,713,895.4)	0.4	>0.9
b_Crotonic.acid	12	16,108,825.9 (23,803,380.1)	23,947,637.5 (26,242,912.3)	8,270,014.3 (20,257,315.3)	0.4	>0.9
b_Succinic.acid	12	407,804.1 (869,276.7)	109,080.2 (267,190.7)	706,528.0 (1,173,394.8)	0.5	>0.9
a_L.Lysine	12	24,416,825.1 (28,518,776.0)	34,566,558.7 (36,434,829.3)	14,267,091.5 (14,648,122.2)	0.5	>0.9
b_Pyridoxal.tent.	12	777,482.7 (1,211,214.3)	598,171.7 (398,509.7)	956,793.7 (1,729,598.9)	0.5	>0.9
b_X2.C.Methyl.D.erythritol4.phosphate.tent.	12	643,051,857.5 (148,219,463.1)	606,454,245.0 (172,899,107.7)	679,649,470.0 (123,382,309.5)	0.5	>0.9
b_X2.Methylsuccinic.acid.tent.	12	287,186,644.6 (143,335,650.3)	264,074,195.0 (155,198,662.0)	310,299,094.2 (140,821,055.1)	0.5	>0.9
b_Pyruvic.acid.tent.	12	150,010,045.5 (9,715,420.7)	147,364,165.0 (6,350,912.8)	152,655,926.0 (12,268,697.7)	0.5	>0.9
a_Niacinamide	12	1,384,815.1 (2,023,883.3)	1,614,438.5 (2,373,808.4)	1,155,191.7 (1,802,752.7)	0.5	>0.9
a_X6.Methoxyquinoline.tent.	12	7,956,394.3 (26,119,894.0)	15,246,370.2 (37,028,395.4)	666,418.3 (1,516,716.5)	0.5	>0.9
a_L_.Methionine	12	788,318.3 (1,316,035.4)	642,601.0 (747,341.7)	934,035.5 (1,789,080.3)	0.5	>0.9
b_X4.Hydroxyquinoline	12	2,294,626.8 (5,198,100.9)	3,743,521.2 (7,079,171.4)	845,732.5 (2,071,613.1)	0.6	>0.9
a_X2.2.6.6.Tetramethyl.4.piperidinol.tent.	12	3,349,971.7 (5,949,414.1)	4,474,480.0 (7,959,519.7)	2,225,463.3 (3,388,416.0)	0.6	>0.9
a_N.N.Diethylethanolamine.tent.	12	3,251,751.6 (3,370,326.9)	2,444,947.7 (2,152,767.5)	4,058,555.5 (4,335,133.4)	0.6	>0.9
b_L.Isoleucine	12	7,328,303.6 (7,854,185.2)	8,665,141.0 (7,496,666.0)	5,991,466.2 (8,673,233.1)	0.7	>0.9
a_X6.Methylquinoline.tent.	12	385.0 (699.5)	274.2 (671.6)	495.8 (772.0)	0.8	>0.9
a_Hypoxanthine	12	38,073.7 (83,225.3)	44,836.3 (109,826.1)	31,311.0 (55,377.5)	0.8	>0.9
b_p.Toluenesulfonic.acid.tent.	12	3,372,499.5 (6,572,551.8)	3,393,943.8 (5,259,090.6)	3,351,055.2 (8,208,375.3)	0.8	>0.9
b_Uroacnic.acid.tent.	12	1,399.0 (2,534.9)	1,818.7 (2,821.3)	979.3 (2,398.9)	0.8	>0.9
a_Pyridoxal.tent.	12	1,928,431.0 (3,031,562.9)	2,203,965.7 (3,922,077.7)	1,652,896.3 (2,157,295.3)	0.8	>0.9
b_X3.Methyl.2.oxovaleric.acid	12	1,101,172.5 (3,039,252.9)	282,158.3 (278,456.3)	1,920,186.7 (4,316,724.3)	0.8	>0.9
b_L.Methionine	12	747,354.3 (822,900.9)	676,740.7 (845,132.3)	817,968.0 (873,813.0)	0.8	>0.9
b_L.Tryptophan	12	198,603.2 (296,935.2)	272,248.2 (407,584.4)	124,958.2 (121,792.6)	0.8	>0.9
a_Indole.3.acrylic.acid	12	2,553,283.9 (3,140,722.0)	2,083,026.7 (2,110,564.8)	3,023,541.2 (4,088,504.8)	0.8	>0.9
b_X4.Dodecylbenzenesulfonic.acid.tent.	12	10,280,591.5 (7,701,423.0)	8,121,727.2 (4,928,645.2)	12,439,455.8 (9,747,256.3)	0.8	>0.9
a_N.Acetylputrescine	12	386,960.3 (468,563.5)	391,056.2 (550,659.6)	382,864.3 (423,966.5)	0.9	>0.9
a_D_.Proline	12	661,884.2 (1,149,335.2)	957,007.0 (1,564,926.8)	366,761.3 (498,103.3)	0.9	>0.9
a_X4.Aminonicotinic.acid.or.isomer.	12	126,303.5 (225,453.7)	94,034.3 (196,574.4)	158,572.7 (265,864.7)	>0.9	>0.9
a_Choline	12	174,331,021.6 (21,492,889.5)	171,722,892.2 (20,170,821.4)	176,939,151.0 (24,353,435.2)	>0.9	>0.9
b_Acetoacetic.acid	12	319,609,159.2 (14,397,923.5)	321,712,028.7 (13,338,036.2)	317,506,289.7 (16,356,781.0)	>0.9	>0.9
a_Isoleucine	12	30,943,808.3 (15,505,575.1)	29,880,732.5 (15,885,905.7)	32,006,884.2 (16,548,594.4)	>0.9	>0.9
b_L.Phenylalanine	12	9,511,810.9 (5,608,112.4)	10,045,803.3 (6,593,135.4)	8,977,818.5 (5,003,823.0)	>0.9	>0.9
a_Creatine	12	137,229.8 (326,719.4)	112,430.3 (275,396.9)	162,029.2 (396,888.8)	>0.9	>0.9
b_D_.Fructose.or.isomer.	12	1,376,324,172.0 (124,013,739.0)	1,382,734,756.2 (112,787,783.2)	1,369,913,587.8 (144,965,454.4)	>0.9	>0.9
b_Folic.acid	12	3,351,599.5 (3,207,090.2)	4,052,769.5 (4,167,729.0)	2,650,429.5 (2,019,416.2)	>0.9	>0.9
b_Propylparaben.or.isomer.	12	255,003.3 (618,051.8)	190,425.0 (466,444.1)	319,581.7 (782,812.0)	>0.9	>0.9

¹ Mean (SD)
² Wilcoxon rank sum test; Wilcoxon rank sum exact test
³ False discovery rate correction for multiple testing


Table 2.

Metabolites released in media from BSA- or palmitate (PA)-treated neurons



SUPPL FIGURE 7

- A.** Graphs showing the latency during the Barnes Test from [Fig 5D](#) with samples distribution and by using the paired comparison method.
- B.** Graphs showing the latency during the Barnes Test from [Suppl Fig S5C](#) with samples distribution and by using the paired comparison method.
- C.** Graphs showing the latency during the Barnes Test from [Fig 5J](#) with samples distribution and by using the paired comparison method.
- D.** Graphs showing the latency during the Barnes Test from [Fig 5k](#) with samples distribution and by using the paired comparison method.
- E.** Graphs showing the alternation during the T Maze Test from [Fig 5E](#) with samples distribution and by using the paired comparison method.
- F.** Graphs showing the alternation during the T Maze Test from [Suppl Fig S5D](#) with samples distribution and by using the paired comparison method.



SUPPL FIGURE 8

A. Graphs showing the ROTAROD results (distance, latency, fall) from [Fig 5F-G-H](#) with samples distribution and by using the paired comparison method.

B. Graphs showing the ROTAROD results (distance, latency, fall) from [Suppl Fig S5E-F-G](#) with samples distribution and by using the paired comparison method.

Graphs showing the ROTAROD results (distance, latency, fall) from [Suppl Fig S5H-I-J](#) with samples distribution and by using the paired comparison method.

References

1. Kleinridders A., Konner A.C., Bruning J.C. (2009) **CNS-targets in control of energy and glucose homeostasis** *Curr Opin Pharmacol* **9**:794–804
2. Grayson B.E., Seeley R.J., Sandoval D.A. (2013) **Wired on sugar: the role of the CNS in the regulation of glucose homeostasis** *Nat Rev Neurosci* **14**:24–37
3. Argente-Arizon P., et al. (2017) **Glial cells and energy balance** *J Mol Endocrinol* **58**:R59–R71
4. Pellerin L., et al. (1998) **Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle** *Dev Neurosci* **20**:291–9
5. Magistretti P.J., Allaman I. (2018) **Lactate in the brain: from metabolic end-product to signalling molecule** *Nat Rev Neurosci* **19**:235–249
6. Belanger M., Allaman I., Magistretti P.J. (2011) **Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation** *Cell Metab* **14**:724–38
7. Suzuki A., et al. (2011) **Astrocyte-neuron lactate transport is required for long-term memory formation** *Cell* **144**:810–23
8. Thaler J.P., et al. (2012) **Obesity is associated with hypothalamic injury in rodents and humans** *J Clin Invest* **122**:153–62
9. Valdearcos M., et al. (2017) **Microglial Inflammatory Signaling Orchestrates the Hypothalamic Immune Response to Dietary Excess and Mediates Obesity Susceptibility** *Cell Metab* **26**:185–197
10. Kim J.D., et al. (2019) **Microglial UCP2 Mediates Inflammation and Obesity Induced by High-Fat Feeding** *Cell Metab* **30**:952–962
11. Yi C.X., et al. (2017) **TNFalpha drives mitochondrial stress in POMC neurons in obesity** *Nat Commun* **8**
12. Vinuesa A., et al. (2019) **Early Exposure to a High-Fat Diet Impacts on Hippocampal Plasticity: Implication of Microglia-Derived Exosome-like Extracellular Vesicles** *Mol Neurobiol* **56**:5075–5094
13. Hao S., et al. (2016) **Dietary obesity reversibly induces synaptic stripping by microglia and impairs hippocampal plasticity** *Brain Behav Immun* **51**:230–239
14. Spencer S.J., et al. (2017) **High-fat diet and aging interact to produce neuroinflammation and impair hippocampal- and amygdalar-dependent memory** *Neurobiol Aging* **58**:88–101
15. Duffy C.M., et al. (2019) **High fat diet increases cognitive decline and neuroinflammation in a model of orexin loss** *Neurobiol Learn Mem* **157**:41–47
16. Benani A., et al. (2012) **Food intake adaptation to dietary fat involves PSA-dependent rewiring of the arcuate melanocortin system in mice** *J Neurosci* **32**:11970–9

17. Wang J., et al. (2001) **Overfeeding rapidly induces leptin and insulin resistance** *Diabetes* **50**:2786–91
18. Gregor M.F., Hotamisligil G.S. (2011) **Inflammatory mechanisms in obesity** *Annu Rev Immunol* **29**:415–45
19. Feng X., et al. (2017) **Microglia mediate postoperative hippocampal inflammation and cognitive decline in mice** *JCI Insight* **2**
20. Pearce E.L., et al. (2013) **Fueling immunity: insights into metabolism and lymphocyte function** *Science* **342**
21. Li H., et al. (2018) **Adipocyte Fatty Acid-Binding Protein Promotes Palmitate-Induced Mitochondrial Dysfunction and Apoptosis in Macrophages** *Front Immunol* **9**
22. Goldmann T., et al. (2013) **A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation** *Nat Neurosci* **16**:1618–26
23. Wakabayashi J., et al. (2009) **The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice** *J Cell Biol* **186**:805–16
24. Gao Y., et al. (2014) **Hormones and diet, but not body weight, control hypothalamic microglial activity** *Glia* **62**:17–25
25. Valdearcos M., et al. (2014) **Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function** *Cell Rep* **9**:2124–38
26. Ackermann W.W., Potter V.R. (1949) **Enzyme inhibition in relation to chemotherapy** *Proc Soc Exp Biol Med* **72**:1–9
27. Hooftman A., O'Neill L.A.J. (2019) **The Immunomodulatory Potential of the Metabolite Itaconate** *Trends Immunol* **40**:687–698
28. Pellerin L (2005) **How astrocytes feed hungry neurons** *Mol Neurobiol* **32**:59–72
29. Bouzier-Sore A.K., et al. (2006) **Competition between glucose and lactate as oxidative energy substrates in both neurons and astrocytes: a comparative NMR study** *Eur J Neurosci* **24**:1687–94
30. Waterson M.J., Horvath T.L. (2015) **Neuronal Regulation of Energy Homeostasis: Beyond the Hypothalamus and Feeding** *Cell Metab* **22**:962–70
31. Goldmann T., et al. (2016) **Origin, fate and dynamics of macrophages at central nervous system interfaces** *Nat Immunol* **17**:797–805
32. Dakic T.B., et al. (2017) **Short-term fasting promotes insulin expression in rat hypothalamus** *Eur J Neurosci* **46**:1730–1737
33. Havel P.J (2001) **Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis** *Exp Biol Med (Maywood)* **226**:963–77
34. Zeltser L.M., Seeley R.J., Tschöp M.H. (2012) **Synaptic plasticity in neuronal circuits regulating energy balance** *Nat Neurosci* **15**:1336–42

35. Garcia-Caceres C., et al. (2019) **Role of astrocytes, microglia, and tanycytes in brain control of systemic metabolism** *Nat Neurosci* **22**:7–14
36. Barca-Mayo O., Lopez M. (2021) **Astrocyte Clocks and Glucose Homeostasis** *Front Endocrinol (Lausanne)* **12**
37. Ikeda H., Yamamoto S., Kamei J. (2021) **Increase in brain l-lactate enhances fear memory in diabetic mice: Involvement of glutamate neurons** *Brain Res* **1767**
38. Buck M.D., et al. (2016) **Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming** *Cell* **166**:63–76
39. Schneeberger M., et al. (2013) **Mitofusin 2 in POMC neurons connects ER stress with leptin resistance and energy imbalance** *Cell* **155**:172–87
40. Ramirez S., et al. (2017) **Mitochondrial Dynamics Mediated by Mitofusin 1 Is Required for POMC Neuron Glucose-Sensing and Insulin Release Control** *Cell Metab* **25**:1390–1399
41. Westergaard N., Sonnewald U., Schousboe A. (1995) **Metabolic trafficking between neurons and astrocytes: the glutamate/glutamine cycle revisited** *Dev Neurosci* **17**:203–11
42. Melo H.M., et al. (2020) **Palmitate Is Increased in the Cerebrospinal Fluid of Humans with Obesity and Induces Memory Impairment in Mice via Pro-inflammatory TNF-alpha** *Cell Rep* **30**:2180–2194
43. Kalsbeek M.J., Mulder L., Yi C.X. (2016) **Microglia energy metabolism in metabolic disorder** *Mol Cell Endocrinol* **438**:27–35
44. Morgunov I.G., et al. (2020) **Microbiological Production of Isocitric Acid from Biodiesel Waste and Its Effect on Spatial Memory** *Microorganisms* **8**
45. Xiong J., et al. (2023) **Dimethyl Itaconate Reduces Cognitive Impairment and Neuroinflammation in APPswe/PS1DeltaE9 Transgenic Mouse Model of Alzheimer's Disease** *Neuromolecular Med* **25**:179–192
46. Serra F.T., et al. (2022) **Resistance exercise improves learning and memory and modulates hippocampal metabolomic profile in aged rats** *Neurosci Lett* **766**
47. Cline B.H., et al. (2012) **The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2** *BMC Neurosci* **13**
48. George S., et al. (2019) **Microglia affect alpha-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease** *Mol Neurodegener* **14**
49. Tay T.L., et al. (2017) **A new fate mapping system reveals context-dependent random or clonal expansion of microglia** *Nat Neurosci* **20**:793–803
50. Tay T.L., et al. (2018) **Unique microglia recovery population revealed by single-cell RNAseq following neurodegeneration** *Acta Neuropathol Commun* **6**
51. Hashimshony T., et al. (2016) **CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq** *Genome Biol* **17**

52. Herman J.S., Sagar D., Grun (2018) **FateID infers cell fate bias in multipotent progenitors from single-cell RNA-seq data** *Nat Methods* **15**:379–386
53. Bhardwaj V., et al. (2019) **snakePipes: facilitating flexible, scalable and integrative epigenomic analysis** *Bioinformatics* **35**:4757–4759
54. Martin M (2011) **Martin, M., Cutadapt removes adapter sequences from high-throughput sequencing reads. 2011, 2011. 17(): p. 3. Cutadapt removes adapter sequences from high-throughput sequencing reads 17**
55. Dobin A., et al. (2013) **STAR: ultrafast universal RNA-seq aligner** *Bioinformatics* **29**:15–21
56. Liao Y., Smyth G.K., Shi W. (2014) **featureCounts: an efficient general purpose program for assigning sequence reads to genomic features** *Bioinformatics* **30**:923–30
57. Grun D (2020) **Revealing dynamics of gene expression variability in cell state space** *Nat Methods* **17**:45–49
58. Salabei J.K., Gibb A.A., Hill B.G. (2014) **Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis** *Nat Protoc* **9**:421–38
59. Shiotsuki H., et al. (2010) **A rotarod test for evaluation of motor skill learning** *J Neurosci Methods* **189**:180–5
60. Illouz T., Madar R., Okun E. (2020) **A modified Barnes maze for an accurate assessment of spatial learning in mice** *J Neurosci Methods* **334**
61. Katoh M., et al. (2017) **Polymorphic regulation of mitochondrial fission and fusion modifies phenotypes of microglia in neuroinflammation** *Sci Rep* **7**
62. Faubert B., et al. (2014) **Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha** *Proc Natl Acad Sci U S A* **111**:2554–9

Editors

Reviewing Editor

Lydia Finley

Memorial Sloan Kettering Cancer Center, New York, United States of America

Senior Editor

Carlos Isales

Augusta University, Augusta, United States of America

Reviewer #1 (Public Review):

In this study, Drougard et al. examined the consequences of an acute high fat diet (HFD) on microglia in mice. 3-day HFD influenced the regulation of systemic glucose homeostasis in a microglia-dependent and independent manner, as determined using microglial depletion with PLX5622. 3-day HFD increased microglial membrane potential and the levels of palmitate and stearate in cerebrospinal fluid in vivo. Using confocal imaging, respirometry and stable isotope-assisted tracing in primary microglial cultures, the authors suggest an increase in mitochondrial fission and metabolic remodelling occurs when exposed to palmitate, which increases the release of glutamate, succinate and itaconate that may alter neuronal metabolism. This acute microglial metabolic response following acute HFD is

subsequently linked to improved higher cognitive function (learning and memory) in a microglia and DRP1-dependent manner.

Strengths:

Overall, this study is interesting and novel in linking acute high fat diet to changes in microglia and improved learning and memory in mice. The role for microglia and DRP1 in regulating glucose homeostasis and memory in vivo appears to be supported by the data. Palmitate (which is elevated in the CSF following acute HFD) is clearly used as a fuel by primary microglia ex vivo as determined using U-13C-palmitate tracing and metabolomics.

Weaknesses:

The authors suggest that utilisation of palmitate by microglia following HFD is the driver of the acute metabolic changes and that the release of microglial-derived lactate, succinate, glutamate and itaconate are causally linked to improvements in learning and memory. A weakness is that the authors provide no mechanistic link between beta-oxidation of palmitate (or other fatty acids) in microglia in vivo and the observed systemic metabolic and memory phenotypes. However, this reviewer acknowledges the technical difficulties of providing this evidence and approaches, such as microglia-specific deletion of CPT1a, will be an exciting avenue of research to explore for a subsequent study.

<https://doi.org/10.7554/eLife.87120.2.sa2>

Reviewer #2 (Public Review):

The study by Drougard et al. aimed to answer a critical question on how high-fat diets trigger metabolic issues like obesity and diabetes. Their study revealed that an acute response by microglial cells in the brain to high-fat intake surprisingly benefits metabolism and cognitive function by rapidly metabolizing harmful fatty acids into alternative energy substrates like lactate and itaconate. Thus, short-term HFD intake seems to prompt a distinct beneficial response, suggesting a need for further exploration into the transition from acute to chronic effects.

<https://doi.org/10.7554/eLife.87120.2.sa1>

Reviewer #3 (Public Review):

Drougard et al. explore microglial detection of a switch to high-fat diet and a subsequent metabolic response that benefits memory. The findings are both surprising and novel in the context of acute high-fat intake, with convincing evidence of increased CSF palmitate after 3 days of HFD. While the authors demonstrate compelling signs of microglial activation in multiple brain regions and unique metabolite release in tracing studies, they should address the following areas.

Major Points:

(1) It appears that the authors perform key metabolic assays in vitro/ex vivo using primary microglia from either neonatal or adult mice, which should be more clearly delineated especially for the 13C-palmitate tracing. In the case of experiments using primary microglia derived from mixed glial cultures stimulated with M-CSF, this system relies on neonatal mice. This is understandable given the greater potential yield from neonatal mice, but the metabolic state and energetic demands of neonatal and adult microglia differ as their functional roles change across the lifespan. The authors should either show that the metabolic pathways they implicate in neonatal microglia are also representative of adult

microglia or perform additional experiments using microglia pooled from adult mice, especially because they link metabolites derived from neonatal microglia (presumably not under the effects of acute HFD) to improved performance in behavioral assays that utilize adult mice.

(2) The authors demonstrate that 3 days of HFD increases circulating palmitate by CSF metabolomics and that microglia can readily metabolize palmitate, but the causal link between palmitate metabolism specifically by microglia and improved performance in behavioral paradigms remains unclear. A previous body of research, alluded to by the authors, suggests that astrocyte shuttling of lactate to neurons improves long-term and spatial memory. The authors should account for palmitate that also could be derived from astrocyte secretion into CSF, and the relative contribution compared to microglia-derived palmitate. Specifically, although microglia can metabolize the palmitate in circulation, there is no direct evidence that the palmitate from the HFD is directly shuttled to microglia and not, for example, to astrocytes (which also express CX3CR1). Thus, the Barnes Maze results could be attributed to multiple cell types. Furthermore, the evidence provided in Figure 5J is insufficient to claim a microglia-dependent mechanism without showing data from mice on HFD with and without microglia depletion (analogous to the third and fourth bars in panel K).

(3) Given the emphasis on improved cognitive function, there is minimal discussion of the actual behavioral outcomes in both the results and discussion sections. The data that HFD-treated animals outperform controls should be presented in more detail both in the figure and in the text. For example, data from all days/trials of the Barnes Maze should be shown, including the day(s) HFD mice outperform controls. Furthermore, the authors should either cite additional literature or provide experimental evidence supporting the notion that microglia release of TCA-associated substrates into the extracellular milieu after HFD specifically benefits neuronal function cellularly or regionally in the brain, which could translate to improved performance in classical behavioral paradigms. The single reference included is a bit obscure, given the study found that increased lactate enhances fear memory which is a neural circuit not studied in the current manuscript. Are there no additional studies on more relevant metabolites (e.g., itaconate, succinate)?

<https://doi.org/10.7554/eLife.87120.2.sa0>

Author response:

The following is the authors' response to the previous reviews.

Public Reviews:

Reviewer #1 (Public Review):

In this study, Drougard et al. examined the consequences of an acute high fat diet (HFD) on microglia in mice. 3-day HFD influenced the regulation of systemic glucose homeostasis in a microglia-dependent and independent manner, as determined using microglial depletion with PLX5622. 3-day HFD increased microglial membrane potential and the levels of palmitate and stearate in cerebrospinal fluid in vivo. Using confocal imaging, respirometry and stable isotope-assisted tracing in primary microglial cultures, the authors suggest an increase in mitochondrial fission and metabolic remodeling occurs when exposed to palmitate, which increases the release of glutamate, succinate and itaconate that may alter neuronal metabolism. This acute microglial metabolic response following acute HFD is subsequently linked to improved higher cognitive function (learning and memory) in a microglia and DRP1-dependent manner.

Strengths:

Overall, this study is interesting and novel in linking acute high fat diet to changes in microglia and improved learning and memory in mice. The role for microglia and DRP1 in regulating glucose homeostasis and memory in vivo appears to be supported by the data.

Weaknesses:

The authors suggest that utilization of palmitate by microglia following HFD is the driver of the acute metabolic changes and that the release of microglial-derived lactate, succinate, glutamate and itaconate are causally linked to improvements in learning and memory. A major weakness is that the authors provide no mechanistic link between beta-oxidation of palmitate (or other fatty acids) in microglia and the observed systemic metabolic and memory phenotypes in vivo. Pharmacological inhibition of CPT1a could be considered or CPT1a-deficient microglia.

We thank Reviewer #1 for their time, effort and the critique. Indeed, we suggest that palmitate drives the aMMR response and associated improvements in learning and memory. In response to acute HFD we observe 1) increased in palmitate in CSF; 2) impaired mitochondrial ETC activity in primary microglia (within 12 hours of HFD); and 3) improved learning and memory. The greatest barrier to proving how acute palmitate uptake in microglia improves learning and memory *in vivo* is the protracted methodology required for microglial isolation and purification. The timeframes and relatively harsh digestion protocols required are currently incompatible with metabolomic tracing and well beyond those required for most cell-types used for metabolomic investigation. We have tested and failed to obtain reproducible data across numerous *in vivo* protocols and finally settled on *in vitro* 13C palmitate treated neonatal microglia as the best current option. Primary neonatal microglia are accepted as one of the current best culture models by the microglial community (Valdercaos cell report 2014, Kim Cell Metab 2019). Using neonatal microglia we demonstrate that 13Cpalmitate label is processed to palmitoylcarnitine (Fig 4C) and acetylcarnitine (Fig 4D) indicating that microglial fatty acid metabolism acts via the canonical CPT1/CPT2 pathway. These experiments highlight that microglia process palmitate via beta oxidation generating acetyl coA and engaging the TCA cycle (Fig 4G-I).

We now acknowledge these technical limitations more clearly and highlight their impact on any conclusions regarding adult microglia *in vivo*:

Results “Microglia take up and metabolize free fatty acids”;

“Due in part to the long isolation times required to generate pure primary adult microglia, metabolite tracing experiments on primary adult microglia are not currently feasible. We therefore chose primary murine neonatal microglia as our model of choice for more mechanistic experiments (Valdercaos, Cell Report 2014)”

And,

Discussion:

“We propose that aMMR could result from direct uptake, processing, and release of fatty acid derived carbons, and demonstrate that microglia are capable of metabolizing fatty acids towards diverse intracellular and extracellular pools.”

While acute ICV injection a CPT1a blocker would be of potential interest, the caveats associated with CPT1a inhibition in other cell-types (neurons, astrocytes, etc) and with targeting the appropriate brain region (currently unknown) currently preclude the effective

use of this approach for to generate clear additional mechanistic insights. Similarly, given the time and resources required to generate, validate, optimize and experiment on a clean model of *in vivo* adult microglia-specific CPT1a knockout, this approach was deemed beyond the scope of this study. That said, the critique is important, and it should comprise a follow-up project.

Comment: Another major weakness is that the authors also suggest that 3-day HFD microglial response (increase membrane potential) is likely driven by palmitate-induced increases in itaconate feedforward inhibition of complex II/SDH. Whilst this is an interesting hypothesis, the in vitro metabolic characterization is not entirely convincing.

The reviewer is correct, we suggest that our data is consistent with a model where a palmitate-induced increase in itaconate inhibits complex II/SDH. While our findings do not comprise mechanistic proof, the hypothesis is supported by our Seahorse studies (Fig 2E) highlighting that a combined Palmitate + Succinate stimulation does not increase OCR beyond that of Palmitate alone; by primary microglial cell experiments highlighting that 3d-HFD treated adult primary microglia are refractory to succinate-induced mitochondrial membrane depolarization (Fig 2F); and by the identification of increased palmitate induced itaconate production/release in cultured primary neonatal microglia (Fig 4H). The data are consistent with an inhibition of complex II/ SDH and with increased itaconate secretion. They are also consistent with literature on more easily accessible myeloid lineages (Lampropoulou V, Cell Metab 2016).

Comment: The authors suggest that acute palmitate appears to rapidly compromise or saturate complex II activity. Succinate is a membrane impermeable dicarboxylate. It can enter cells via MCT transporters at acidic pH. It is not clear that I) Succinate is taken up into microglia, II) If the succinate used was pH neutral sodium succinate or succinic acid, and III) If the observed changes are due to succinate oxidation, changes in pH or activation of the succinate receptor SUCNR1 on microglia. In the absence of these succinate treatments, there are no alterations in mitochondrial respiration or membrane potential following palmitate treatment, which does not support this hypothesis.

We thank Reviewer #1 for highlighting a lack of information in the material and methods. We have updated them accordingly as follows:

“For the electron transport chain experiments (ETC), the experiment was based on the Salabei et al. The cell suspension was incubated with the mitochondrial probe Tetramethylrhodamine TMRM (10mM; Abcam, Cat# ab228569) and fluorescent glucose analog 2-NBDG (Abcam, Cat# 235976) for 30min at 37degrees before FACS acquisition. For challenging the ETC, the cell pellet was resuspended in 500ul of warm MAS buffer solution + 1nM Plasma Membrane Permeabilizer (Agilent Seahorse XF PMP) in order to permeabilize the cells. Microglial cells were gated from CD45low-CD11b+ cells followed by singlet after forward and side scatter pattern. They were incubated each 90 seconds by the following drugs: 0,5ul of 100uM Rotenone (Sigma), 2ul of 2.5M Succinate adjusted to pH 7.4 with NaOH (succinic acid, Sigma) and 0.5ul of 1mM Antimycin (Sigma). Cytometry was performed on Fortessa (BD Bioscience) and analyzed with FlowJo v10 (Treestar).”

Following the updated protocol, we hope we highlighted that the succinate (solution of succinic acid pH 7.4) is reaching directly the ETC since the microglial cells have been permeabilized by the Plasma Membrane Permeabilizer (Agilent Seahorse XF PMP).

Comment: Intracellular itaconate measurements and quantification are lacking and IRG1 expression is not assessed. There also appears to be more labelled itaconate in neuronal cultures from control (BSA) microglia conditioned media, which is not discussed. What is the total level of itaconate in neurons from these conditioned media

experiments? No evidence is provided that the in vivo response is dependent on IRG1, the mitochondrial enzyme responsible for itaconate synthesis, or itaconate. To causally link IRG1/itaconate, IRG1-deficient mice could be used in future work.

We appreciate the interest, the exciting question, and the suggested future experiment. Indeed, our results suggest a difference in metabolite release between the BSA treated-microglia and palmitate treated-microglia and their impact on neurons comprises a prime question for future work. We have highlighted this in the discussion as well as adding a comment regarding relative levels of labelled itaconate as follows:

Results; Acute HFD induces widespread MMR and rapid modulation (...) memory

“As a control for the direct uptake of ¹³C-glucose, we treated parallel neuronal cultures with the same fresh ¹³C-glucose tracing media originally added to the microglia. Intriguingly, and consistent with literature documenting poor direct glucose utilization by neurons [29], we found substantial m+3 lactate (as well as other metabolites) in neurons treated with microglial conditioned media, and at levels that far exceeded labelling triggered by glucose tracer alone (Fig 5A, middle column vs left column)(Suppl Fig S5B). The data indicate higher uptake of citrate and itaconate from the control microglia-conditioned media, further supporting the hypothesis that neuronal metabolism is reproducibly impacted by palmitate-triggered changes in microglial products. These data demonstrate that palmitate metabolism by microglia modulates neuronal carbon substrate use *in vitro*, and, they highlight the relative importance of this process compared to uptake of pure glucose. The data identify a candidate mechanism by which aMMR may alter neuronal function *in vivo*.”

Comment: While microglial DRP1 is causally implicated the role of palmitate is not convincing. Mitochondrial morphology changes are subtle including TOMM20 and DRP1 staining and co-localization - additional supporting data should be provided. Electron microscopy of mitochondrial structure would provide more detailed insight to morphology changes. Western blot of fission-associated proteins Drp1, phospho-Drp1 (S616), MFF and MiD49/51. Higher magnification and quality confocal imaging of DRP1/TOMM20. Drp1 recruitment to mitochondrial membranes can be assessed using subcellular fractionation.

We appreciate the reviewer’s comment. Previous work by others, already cited elsewhere in our manuscript

(PMCID: PMC7251564), has clearly demonstrated increased mitochondrial fragmentation and phosphorylated DRP1 in 3d HFD animals. This very specific result can therefore be considered confirmatory / validating of existing literature, and important for inclusion of DRP1 in our overall model. We have made sure to better highlight this important literature accordingly:

Results; A rapid Microglial Mitochondria response to high fat diet

“Consistent with the *in vivo* observations above, *in vitro* palmitate exposure decreased microglial mitochondrial length within 24 hours, indicating that fatty acid exposure itself is sufficient to trigger mitochondrial fission in a cell autonomous manner (Fig 2G upper panels). This result also confirms observations by Kim et al. who observed mitochondrial fission and DRP1 phosphorylation upon 3d-HFD treated mice [Kim JD et al, Microglial UCP2 mediates Inflammation and Obesity induced by High Fat feeding, Cell Metab 2019].”

Comment: No characterization of primary microglia from DRP1-knockout mice is performed with palmitate treatment. Authors demonstrate an increase in both stearate and palmitate in CSF following 3day HFD. Only palmitate was tested in the regulation of

microglial responses, but it may be more informative to test stearate and palmitate combined.

Testing stearate and palmitate combined is an interesting experiment for mimicking the global effect of HFD which is highly enriched with these two saturated fatty acids, and then, more informative. *In vitro* stimulation of microglia model cells has been previously published by Valdearcos and al. (Cell Reports 2014) who studied the effect of a mix of stearate and palmitate on the Mediobasal Hypothalamus inflammation. Here, we build on their important findings by demonstrating that these 2 compounds are actually found in the CSF of 3d-HFD mice. Studies from other labs have also shown the presence of stearate and palmitate in the CSF of chronically obese and diabetic patients which highlights the importance of these findings (Melo HM et al. cell report 2020). While a systematic dissection of the roles of HFD-regulated CSF metabolites (including direct (diet containing) and indirect (secondary)) is beyond the scope of this study, this point is important, not least because it highlights less well-studied metabolites and the potential of possible combinatorial interactions. We have highlighted this idea in the results as follows:

Results; A rapid Microglial Mitochondria response to high fat diet

“To test whether these observed fatty acid changes in the CSF might directly trigger aMMR, we switched to an *in vitro* primary neonatal microglia model and examined the effects of the more abundant of these, palmitate (Fig S2A-B).”

and, in the discussion as follows:

“Studies have identified stearate and palmitate in the CSF of patients with chronic obesity and with diabetes, reports that highlight the importance of these findings (Melo HM et al. cell report 2020). While a systematic dissection of the roles of HFD-regulated CSF metabolites (including direct (diet containing) and indirect (secondary)) is beyond the scope of this study, they represent priority areas for future investigation, particularly given the wide-range of fatty-acid specific biological effects in the literature, and the potential for combinatorial interactions.”

Reviewer #1 (Recommendations For The Authors):

Congratulations on this interesting and novel work. Please see public review for details on potential experiments. While I would not expect all the experiments to be performed for this current study, it's important to not overstate what the data is showing. For example, there is no causal link between palmitate oxidation in microglia or released metabolites (itaconate etc) from microglia in the effect on systemic glucose metabolism or memory. To make such claims more supporting data would be required.

We thank Reviewer #1 for their highly constructive critique_._

Reviewer #2 (Public Review):

*The study "A rapid microglial metabolic response controls metabolism and improves memory" by Drougard et al. provides evidence that short-term HFD has a beneficial effect on spatial and learning memory through microglial metabolic reprogramming. The manuscript is well-written and the statistics were properly performed with all the data. However, there are concerns regarding the interpretation of the data, particularly the gap between the *in vivo* observations and the *in vitro* mechanistic studies.*

In the PLX-5622 microglial depletion study, it is unclear what happened to the body weight, food intake, and day-night behavior of these mice compared to the vehicle control mice. It is important to address the innate immunity-dependent physiology

affected by a long period of microglial depletion in the brain (also macrophages in the periphery). Furthermore, it would be beneficial to validate the images presented in Fig.1F by providing iba1 staining in chow diet-fed mice with or without PLX-5622 for 7-10 days. Additionally, high-quality images, with equal DAPI staining and comparable anatomical level, should be provided in both chow diet-fed mice and HFD-fed mice with or without PLX-5622 in the same region of hypothalamus or hippocampus. These are critical evidences for this project, and it is suggested that the authors provide more data on the general physiology of these mice, at least regarding body weight and food intake.

We are grateful to Reviewer #2 for their constructive comments and for their time and effort; and for highlighting the lack of experimental details regarding the PLX-5622 microglial depletion study. We followed the protocol established in Feng et al JCI 2017. No adverse effects on body weight, food intake and day-night behavior have been described in this study as well as in other studies for longer treatment (Sonia George et al Molecular Neurodegeneration 2019). We didn't observe any differences in body weight and the food intake within or between groups, upon PLX administration. These data have been included as new Supplementary Fig 6 A-B.

The material and method was updated as follows:

“Animals were administered PLX5622-containing diet for 7-9 days without observable impact on the body weight or food intake (Fig S6A-B), using protocols adopted from [Feng et al JCI 2017, Sonia George et al Molecular Neurodegeneration 2019].”

Comment: It is also unclear whether the microglia shown in Fig.3A were isolated from mice 4 weeks after Tamoxifen injection. It is suggested that the authors provide more evidence, such as additional images or primary microglia culture, to demonstrate that the mitochondria had more fusion upon drp1 KO. It is recommended to use mito-tracker green/red to stain live microglia and provide good resolution images.

We thank Reviewer #2 for pointing out the lack of detailed information about Fig 3A. Microglial cells were indeed isolated from mice after the tamoxifen injection for highlighting the deletion. We updated the Material and methods with the text below;

“For the colocalization experiment, microglia were isolated from 10 to 12-week old drp1ko mice and their littermate controls, immediately fixed in PFA and stained with DRP1 (diluted 1:50 Cell signaling; Cat#8570) and tomm20 antibodies (diluted 1:1000, SantaCruz; Cat#sc177615).”

This experiment was performed as an additional control of the drp1 deletion from our knockout-mice. For this experiment we used Tomm20 since the microglia cells weren't live after the addition of PFA.

Comment: Regarding the data presented in Fig.5A, it is suggested that the authors profile the metabolomics of the microglial conditioned media (and provide the methods on how this conditioned media was collected) to determine whether there was already abundant lactate in the media. Any glucose-derived metabolites, e.g. lactate, are probably more preferred by neurons as energy substrates than glucose, especially in embryonic neurons (which are ready to use lactate in newborn brain).

With regards to Fig 5A, metabolomics of microglia conditioned media are provided as Fig 5A, Supp Figure 5B and we provided a supplementary table 2.

We thank Reviewer #2 for noting the lapse of technical detail. We updated the Material and methods with the following:

“For conditioned media experiments, microglial cells were incubated with DMEM (Gibco) without lactate completed with BSA-conjugated palmitate or Control BSA. Conditioned media was collected after the incubation, centrifuged 15min at 300g (40C) and the supernatant transferred and frozen in a fresh tube avoiding the cells and debris pellet. Sample were immediately snap frozen or use for the neurons incubation.”

Any glucose-derived metabolites, e.g. lactate, are more preferred by neurons as energy substrates than glucose as described first in the literature by Prof. Pellerin and Prof. Magistretti via the astrocyte-neuron cooperation (PNAS 1994). Since their discovery, lactate has been explored and is well known as a key signaling molecule (Magistretti PJ Nat Rev Neurosciences 2018). We explored the role of lactate released from the microglia, and we demonstrated that it is taken up by neurons independently of any microglial pretreatment. This experiment highlights microglia as another lactate provider for the neurons (Fig 4N and Fig 5A).

Comment: Finally, it is important to address whether PLX-5622 affects learning and spatial memory in chow diet-fed animals. Following the findings shown in Fig 5J and 5K, the authors should confirm these by any morphological studies on synapse, e.g. by synaptophysin staining or ultrastructure EM study in the area shown in Fig 5I.

We appreciate the comment and question. We performed the controls and included them now as Fig 5J and Fig S5 E-F-G. We do not observe any adverse effects of PLX5622 on learning and spatial memory in normal chow-fed animals.

While we were unable to study the synapses as requested, it is important to note that no changes are expected given publications from other labs using the same protocol (Feng x JCI 2017 ,Spangenberg E Nat Com 2019), or longer PLX5622 treatment (Niiyama T eNeuro 2023, Witcher KG J neurosciences 2021), all four of which did not find morphological differences at synapses.

Reviewer #2 (Recommendations For The Authors):

The authors should provide more evidence that palmitate is derived from HFD to prove that it mediates the HFD effects on the microglial mitochondria response. This could be done by adding 13C-palmitate into the HFD and performing metabolomics in isolated microglia from control mice (and Drp1-MG-KO mice, if possible).

We thank the Reviewer #2 for the enthusiastic revision. Unfortunately, we were unable to attempt this final suggested experiment. We have adjusted our wording accordingly and appreciate the reviewer’s understanding.

Reviewer #3 (Public Review):

Drougard et al. explore microglial detection of a switch to high-fat diet and a subsequent metabolic response that benefits memory. The findings are both surprising and novel in the context of acute highfat intake, with convincing evidence of increased CSF palmitate after 3 days of HFD. While the authors demonstrate compelling signs of microglial activation in multiple brain regions and unique metabolite release in tracing studies, they should address the following areas prior to acceptance of this manuscript.

Major Points:

(1) It appears that the authors perform key metabolic assays in vitro/ex vivo using primary microglia from either neonatal or adult mice, which should be more clearly delineated especially for the 13C-palmitate tracing. In the case of experiments using

primary microglia derived from mixed glial cultures stimulated with M-CSF, this system relies on neonatal mice. This is understandable given the greater potential yield from neonatal mice, but the metabolic state and energetic demands of neonatal and adult microglia differ as their functional roles change across the lifespan. The authors should either show that the metabolic pathways they implicate in neonatal microglia are also representative of adult microglia or perform additional experiments using microglia pooled from adult mice, especially because they link metabolites derived from neonatal microglia (presumably not under the effects of acute HFD) to improved performance in behavioral assays that utilize adult mice.

We thank Reviewer #3 for their constructive critique and encouraging words. As indicated, the 13C-palmitate experiments were performed with primary microglia derived from mixed glial cultures stimulated with M-CSF and we demonstrated our primary cultures were almost pure by the supplementary experiments (supp Fig2A and B). Additional minor details in these contexts have been added to the Material and Methods.

The experiments focusing on the mitochondrial ETC were performed on sorted microglia from adult mice and parallels demonstrated with the neonatal cultures (the primary model for metabolic tracing). Compromised complex II activity under conditions of acute HFD/palmitate stimulation for instance were shown in both systems. Unfortunately, despite best-efforts, attempts to run 13C-palmitate tracing experiments on primary adult microglia failed, attributable in large part to the long (~4 hour) and harsh microglial extraction and sorting process. These experiments will require substantial follow-up efforts including the establishment and validation ideally of an adult microglia-neuron co-culture model that faithfully recapitulates most aspects of in vivo metabolic cross-talk. This noble aim is beyond the scope of this study. We have made sure to temper the conclusions made in the manuscript and to not overstate the impact and interpretation of the *in vitro* work including updating the following sentences.

Results “Microglia take up and metabolize free fatty acids”;

“Due in part to the long isolation times required to generate pure primary adult microglia, metabolite tracing experiments on primary adult microglia are not currently feasible. We therefore chose primary murine neonatal microglia as our model of choice for more mechanistic experiments (Valdercaos cell Report 2014)”

and Discussion:

“We propose that aMMR could result from direct uptake, processing, and release of fatty acid derived carbons, and demonstrate that microglia are capable of metabolizing fatty acids towards diverse intracellular and extracellular pools.”

Comment: The authors demonstrate that 3 days of HFD increases circulating palmitate by CSF metabolomics and that microglia can readily metabolize palmitate, but the causal link between palmitate metabolism specifically by microglia and improved performance in behavioral paradigms remains unclear. A previous body of research, alluded to by the authors, suggests that astrocyte shuttling of lactate to neurons improves long-term and spatial memory. The authors should account for palmitate that also could be derived from astrocyte secretion into CSF, and the relative contribution compared to microglia-derived palmitate. Specifically, although microglia can metabolize the palmitate in circulation, there is no direct evidence that the palmitate from the HFD is directly shuttled to microglia and not, for example, to astrocytes (which also express CX3CR1).

We appreciate the comment. Indeed, this issue highlights one of the greatest challenges for efforts aimed at tracing (beyond doubt) that a single minor cell population contributes towards metabolic cross-talk in vivo. Our experiments show: increased CSF palmitate levels

within one feeding cycle of HFD; rapidly induced microglial metabolic activation (characterized by increased mitochondrial membrane potential and impaired complex II activity); and that microglia mount a comparable mitochondrial activation profile in vitro when exposed to palmitate. They show in vitro using neonatal microglia that microglia take up and metabolize palmitate; that they release metabolites with neuro-modulatory potential; that neurons take these metabolites up and modulate their function differentially when exposed to control vs palmitate-treated microglia-conditioned media (in the absence of astrocytes). The experiments show through acute PLX-induced elimination of microglia, however crude, that this compartment impacts the acute HFD response, and using conditional deletion, that full DRP1 expression is required CX3CR1-CreERT2 targeted cells (primarily microglia deleting; Zhao et al 2019). While these experiments cannot rule out a contribution of astrocytes to the observations in vivo, comparable experiments rarely can and we cannot rationalize why microglia should not have equal access to CSF palmitate for uptake or to neurons for substrate provisioning. We now better highlight this important issue, and temper our conclusions accordingly:

“Tanycytes and astrocytes have both been documented to release select metabolites into the extracellular environment [33, 34]. While suggestive, the experiments highlighted here do not rule out a contribution of these or cell types in coupling acute HFD intake to memory and learning.”

Comment: Thus, the Barnes Maze results could be attributed to multiple cell types. Furthermore, the evidence provided in Figure 5J is insufficient to claim a microglia-dependent mechanism without showing data from mice on HFD with and without microglia depletion (analogous to the third and fourth bars in panel K).

Agreed. We appreciate the comment. We have now added the requested HFD condition to Figure 5J. The data support our previous interpretation of the data.

Comment: Given the emphasis on improved cognitive function, there is minimal discussion of the actual behavioral outcomes in both the results and discussion sections. The data that HFD-treated animals outperform controls should be presented in more detail both in the figure and in the text. For example, data from all days/trials of the Barnes Maze should be shown, including the day(s) HFD mice outperform controls. Furthermore, the authors should either cite additional literature or provide experimental evidence supporting the notion that microglia release of TCA-associated substrates into the extracellular milieu after HFD specifically benefits neuronal function cellularly or regionally in the brain, which could translate to improved performance in classical behavioral paradigms. The single reference included is a bit obscure, given the study found that increased lactate enhances fear memory which is a neural circuit not studied in the current manuscript. Are there no additional studies on more relevant metabolites (e.g., itaconate, succinate)?

We agree. We have now re-plotted the behavioral test to better highlight that the HFD-treated animals outperform controls, as requested (Fig S7 and S8). We also added the requested literature. While we cannot be sure our search captured all relevant studies, we find a relative paucity of studies that characterize CSF metabolite changes in the context of acute high fat feeding or that demonstrate the ability of CSF substrates to convincingly improve memory and learning in vivo at physiological levels. Indeed, while simple, we feel the findings are of substantial novelty and highlight an area for significant future research. We have tempered our conclusions throughout and added to the discussion as follows:

“Such substrate release could mediate the learning and memory effects that accompany aMMR; they are consistent with the data of other studies that have examined metabolite associations with learning and memory (itaconate [Morgunov IG, microorganisms 2020;

Xiong J, Neuromolecular med 2023], succinate [Serra FT neurosciences letter 2022; Cline BH, BMC neurosciences 2012].”

Minor Points:

(1) In Figure 5J the latency to find the hole was noticeably higher (mean around 150s) than the latency in panel K (mean around 100s for controls, and 60s for Drp1MGWT on HFD). This suggests high variability between experiments using this modified version of the Barnes Maze, despite the authors assertion that a standard Barnes Maze was employed and the results were reproducible at multiple institutions. Why do Drp1MGWT mice on control diet find the escape hole significantly faster than WT mice on control diet in panel J? Given the emphasis on cognitive improvement following acute HFD as a novel finding, the authors should explain this discrepancy.

We appreciate this question and comment. Indeed, as the reviewer knows, behavioral tests including the Barnes test show variation with genetic background, and with environment and context (eg. age, caging density, litter size, behavioral state and more (Inglis A, Physiol Behavior 2019; Loos M Mamm Genome 2015; and unpublished observations). We do not know the exact origin of the difference mentioned above but our best guess would be that it stems from either environmental differences that are ever present in vivaria (seasonal, mouse house room, cage-changing cycles, etc) and/or, differences between the background genetics (eg. presence of Cre transgene and linked genome, genetic drift) or precise experimental differences between the cohorts (eg. repeated tamoxifen-injection paradigm for the deletion group). All of our experiments were performed in parallel, with all relevant animal groups equally represented in every run, and, and used age- and sex-matched individuals from congenic strains. Wherever possible, controls and test animals were *littermates* to minimize within strain variance attributable to litter effects (litter size, maternal and paternal effects). Given our lab’s interest and focus on the mechanistic and developmental origins of variance heterogeneity, these differences are of high interest for future study.

Comment: The authors highlight in the graphical abstract and again in Figure 4A the formation of lipid droplets following palmitate exposure as evidence of that microglia can process fatty acids. They later suggest that a lack of substantial induction of lipid droplet accumulation suggests that microglia are metabolically wired to release carbon substrates to neighboring cells. Clarification as to the role of lipid droplet formation/accumulation in explaining the results would eliminate any possible confusion.

We modified the wording in the manuscript accordingly:

Results “Microglia take up and metabolize free fatty acids”;

“Based on BODIPY fluorescence, we found that primary microglia increase lipid droplet numbers within 24h of *in vitro* exposure to palmitate (200uM; Fig 4A), demonstrating a capacity to take up fatty acids.”

Comment: In many bar graphs showing relatively modest effects, it would be helpful to use symbols to also show the distribution of sample and animal replicates (especially behavioral paradigms).

Agreed. Indeed, the results are both modest and impressive given the nature of the intervention (simple change in dietary macronutrient composition). We have now re-plotted the results from the behavioral experiments, accordingly (Fig S7 and Fig S8).

Reviewer #3 (Recommendations For The Authors):

This is a good manuscript deserving of publication assuming some of the concerns posed above are addressed.

We thank Reviewer #3 again for their time, effort, and dedication, and for their objective review of the manuscript.

<https://doi.org/10.7554/eLife.87120.2.sa4>